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Cardiovascular disease (CVD) has accounted for more deaths than any other major cause 
of death in the United States every year since 1900, with the exception of 1918. Despite 
improvements in the management of CVD, there is still a need for new and improved 
treatments and diagnostics. In peripheral artery disease (PAD), treatment with pro-
angiogenic growth factors, such as vascular endothelial growth factor (VEGF), is currently 
being explored. However, there is a need to overcome limitations of this therapy, such as 
the growth factor’s short half-life, inadequate delivery to target tissue, and inadequate 
retention at target tissue. In myocarditis, a large number of patients go undiagnosed due 
to the disease’s heterogeneous etiology, pathophysiology, and clinical presentation. 
Current diagnostic techniques, such as endomyocardial biopsy and cardiac magnetic 
resonance, are inadequate, and there is a need for new technologies for the appropriate 
diagnosis and timely treatment of myocarditis. This dissertation aims to explore two 
different targeting technologies for the treatment and diagnosis of PAD and myocarditis. 
 
In PAD, ischemic tissue undergoes necrosis and releases cellular contents, including 
DNA, into extracellular space. A modified Hoechst compound has been previously used 
to target extracellular DNA in an animal model of myocardial infarction. We explored using 
a similar modified Hoechst compound to target extracellular DNA in an animal model of 
PAD and deliver VEGF to ischemic tissue. Despite promising initial results, we did not 
observe any significant improvements in the retention or targeting of our compound to 
ischemic tissue when compared to controls. 
 
Myocarditis is characterized by the presence of localized or diffuse inflammatory infiltrates 
in the myocardium. In an animal model of myocarditis, we used an in vivo phage display 
xvii 
 
library to identify peptides that preferentially targeted this diseased myocardium. Ex vivo 
screening of potential peptides was then used to identify two peptides whose binding 
correlated with disease severity. In vivo screening of these two peptides was then used to 
demonstrate that one of the peptide’s binding correlated with disease severity. 
Immunohistochemistry and proteonomic analysis were then used to demonstrate that this 
peptide colocalizes with immune cells in inflammatory infiltrates and binds to intracellular 
contents that are released into extracellular space during myocarditis. 
 
Through these approaches, two different techniques for the treatment and diagnosis of 
CVD have been explored. These insights will advance the development of new techniques 




CHAPTER 1: INTRODUCTION 
 
Cardiovascular disease (CVD) has accounted for more deaths than any other major cause 
of death in the United States every year since 1900, with the exception of 1918 [1, 2] . In 
fact, 1 person dies every 40 seconds due to CVD [1]. Furthermore, the direct and indirect 
costs of CVD were estimated to be around $320 billion in 2011, a number that is expected 
to increase to $918 billion by 2030 [1]. Despite improvements in the management of CVD, 
there is still a need for new and improved treatments and diagnostics, particularly for 




PAD is characterized by the presence of ischemia and necrosis [3, 4], and treatment with 
pro-angiogenic growth factors, such as vascular endothelial growth factor (VEGF), is 
currently being explored [4-6]. However, there is a need to overcome limitations of this 
therapy, such as the growth factor’s short half-life, inadequate delivery to target tissue, 
and inadequate retention at target tissue [5, 7, 8]. 
 
Myocarditis refers to localized or diffuse inflammation of the myocardium [9-11]. A large 
number of patients with myocarditis go undiagnosed due to the disease’s heterogeneous 
etiology, pathophysiology, and clinical presentation [9, 12]. Current diagnostic techniques, 
such as endomyocardial biopsy and cardiac magnetic resonance, are inadequate, and 
there is a need for new technologies for the appropriate diagnosis and timely treatment of 




1.2: Specific Aims 
 
Our central hypothesis is that targeting technologies can improve current treatments and 
diagnosis of CVD. This dissertation aims to explore two different targeting technologies 
for the treatment and diagnosis of PAD and myocarditis.  
 
Specific Aim 1: To evaluate the targeting potential of Hoechst compounds. 
We hypothesized that Hoechst compounds would improve the retention and targeting of 
VEGF in an animal model of hindlimb ischemia (HLI). Two different targeting compounds 
were synthesized, HoVEGFmp and HoVEGF165. To asses each compounds’ bioactivity, 
in vitro permeability assays, Western blot analysis, and tube formation assays were 
performed. To assess the retention and targeting of these compounds, each compound 
was delivered through an intramuscular or intravenous injection to animals with HLI 
followed by fluorescent imaging. We did not observe any improvements in the retention or 
targeting of our compound when compared to appropriate controls. 
 
Specific Aim 2: To identify and evaluate targeting peptides for myocarditis.  
We hypothesized that we could identify peptides that would preferentially target the hearts 
of animals with myocarditis. To identify potential targeting peptides, an in vivo phage 
display library was used in animal model of myocarditis. Six of the identified peptides were 
then screened ex vivo on frozen sections from the hearts of animals with and without 
myocarditis. Two of these peptides were then screened in vivo using fluorescent imaging. 
Finally, the binding targets of one of these peptides were assessed using 
immunohistochemistry and proteonomic analysis. We identified one peptide whose 
binding correlated with disease severity in vivo. We determined that this peptide 
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colocalized with immune cells in inflammatory infiltrates and bound to intracellular contents 




CHAPTER 2: LITERATURE REVIEW 
 
2.1: Peripheral Artery Disease 
 
2.1.1: Epidemiology 
Peripheral artery disease (PAD) affects between 8-10 million people in the United States, 
although estimates suggest that incidence could be as high as 18-21 million people with 
better diagnostic modalities and increased awareness [1, 13, 14]. The prevalence of PAD 
is estimated to be 10-25% in people over the age of 55, with higher prevalence observed 
among the elderly, non-Hispanic blacks and women [1, 3]. Globally, about 202 million 
people are living with PAD, with a 13-29% increase in the number of individuals with PAD 
in the last decade [1, 3, 13, 14]. In 2011, PAD any mention mortality in the United States 
was 62,183 people (age-adjusted death rate of 18.1 per 100,000 people), with PAD being 
the underlying cause of 13,484 of those deaths [1]. 
 
PAD is associated with hypertension, diabetes mellitus (DM), chronic kidney disease, and 
smoking [1]. It is also associated with significant morbidity. Patients with PAD report 
impaired function and quality of life, which is true even in patients that are currently 
asymptomatic [1]. Between 40-60% of patients with PAD will develop some degree of 
coronary or cerebrovascular disease [13, 14]. For patients with more severe critical limb 
ischemia (CLI), mortality rate can be as high as 20-25% at one year after presentation, 
and 40-70% at five years after presentation [3, 15]. It estimated that $4.37 billion are spent 
every year in the treatment and management of PAD, with most expenditures associated 




2.1.2: Risk Factors 
Risk factors for PAD are similar to the risk factors of other cardiovascular diseases such 
as coronary artery disease [1, 3]. Known risk factors include male gender, age greater 
than 50, African American ethnicity, family history of vascular disease, smoking, 
hyperlipidemia, hypertension, DM, lifestyle (diet and exercise), hyperhomocysteinemia, 
and inflammation [1, 13, 15]. The two strongest risk factors for PAD are cigarette smoking 
and DM, with odds ratios of 1.88 and 2.72 respectively [1, 16]. Smoking cessation has 
been linked to a decrease in the incidence of PAD and improved outcomes in patients with 
intermittent claudication (IC) or who undergo surgical intervention [13]. For DM patients, 
a 1% increase in hemoglobin A1c (HbA1c) has been associated with a 26% increase in 
PAD risk, and even insulin resistance in the absence of DM increases the risk of PAD by 
40-50% [3, 13]. 
 
2.1.3: Pathophysiology 
PAD is the occlusion of peripheral arteries caused mainly by atherosclerosis and 
associated thrombosis, although other causes such as vasculitis and in situ thrombosis 
caused by hypercoagulable states have been reported [3]. Atherosclerosis is a chronic 
inflammatory process that begins with the dysfunction of vascular endothelial cells (ECs) 
that leads to the accumulation of lipids and the infiltration of monocytes in the intima of an 
artery [5, 17, 18]. Monocytes differentiate into macrophages, engulf the lipids present in 
the intima of the affected artery, and become foam cells [5, 17, 18]. At the same time 
vascular smooth muscle cells migrate to the intima, synthesize extracellular matrix, and 
form a fibrous cap [5, 16, 18]. Foam cells continue to release pro-inflammatory signals 
that enhance local inflammation and promote plaque growth [17]. Proteolysis and 
disruption of the atherosclerotic plaque eventually leads to the rupture of the plaque and 
the exposure of thrombogenic material into arterial circulation [17]. The thrombogenic 
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material causes platelets to adhere and aggregate, activating the coagulation cascade 
and creating a thrombus that prevents the blood flow through the peripheral arteries [5, 
16-18]. 
 
The response to this gradually progressive limb ischemia involves the increase in blood 
flow through the promotion of angiogenesis and arteriogenesis, along with the activation 
other processes implicated in the ischemic response such as vascular remodeling, 
inflammation and apoptotic pathways [3]. In patients with the more severe CLI, these 
processes become ineffective, which leads to an on-going inadequate perfusion of tissue, 
depriving myocytes of oxygen and other nutrients [3, 4]. Within hours, these cells become 
either apoptotic and/or terminally necrotic, losing the ability to be rescued even with 
reperfusion therapy [19-21].  
 
Apoptosis, which also known as the physiological pathway of cell death, is the mechanism 
used to clear cells that have become superfluous or aberrant in function [22]. It is 
characterized by a series of tightly regulated biochemical processes in which a cell 
becomes apoptotic bodies that contain nuclear contents and cell organelles [22]. These 
apoptotic bodies are then cleared by either macrophages or neighboring cells through 
phagocytosis, without releasing cellular contents into extracellular space [21, 22]. In 
contrast, necrosis, which is also known as the pathological pathway of cell death, is usually 
triggered by external disturbances such as hypoxia [22]. It is characterized by a slight 
initial cellular swelling followed by cell lysis and the release of cellular contents, including 
DNA, into extracellular space [21-23]. 
 
In patients with CLI, large areas of tissue damage and necrosis may be present, which 
may appear as ulcers and gangrene [3]. Since in the order of picograms of DNA are 
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present in each myocyte, these large areas of necrosis release large quantities of 
intracellular DNA into extracellular space [21, 23]. Although this DNA can be collected and 
measured in the blood of patients with PAD [24, 25], the concentration in blood is much 
lower than that found in the necrotic tissue itself, probably due to the diluting effect of the 
large volume of blood and the presence of serum nucleases [21]. Myocyte necrosis, 
depending on its extent, may lead to impaired healing, decreased muscle mass, disease 
progression, and loss of normal muscle function, causing significant morbidity and 
mortality [1, 26, 27]. 
 
2.1.4: Clinical Presentation 
Although the two most widely described clinical presentations of PAD are IC and CLI, 
patients can present with a wide range of symptoms [5, 15, 28]. About 40% of PAD 
patients are asymptomatic, 10% present with IC, and about 50% present with symptoms 
different from classic claudication [1]. Only 1-3% of PAD patients present with the more 
severe CLI [29]. Patients with IC have insufficient blood flow during exercise [4, 5, 15], 
and they can be can be subdivided based on the degree of limitations observed. Patients 
with mild claudication show no limitations in walking, patients with moderate claudication 
show the ability to walk without stopping for more than 2 blocks or 200 meters or 4 minutes, 
while patients with severe claudication show the ability to only walk up to 2 blocks or 200 
meters or 4 minutes [28]. In patients with the more severe CLI, blood flow is inadequate 
even at rest [4, 5, 15], and these patients can present with ischemic rest pain in the distal 
leg, ischemic ulcers on the distal leg, and ischemic gangrene [28]. It is important to note 
that this classification does not take into account different lesion and vessels 
characteristics, which may be important indicators of disease progression [28]. For 
example, patients can be classified based on other parameters such as the degree of 
peripheral artery stenosis, the length of the lesions observed, the degree of lesion 
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calcification, and the anatomic level of occlusions observed [28]. Understanding of the 
complex clinical presentation of patients with PAD is important, particularly when 
determining the proper clinical interventions and when comparing the efficacy of different 
novel therapies. 
 
Although most asymptomatic patients will remain symptom free throughout the course of 
the disease, about 7-15% of these patients will progress to IC within five years [15]. Of 
these patients with IC, about 20-25% will experience further disease progression, with 1-
3% requiring major amputation within five years [15]. A Gradual disease progression from 
asymptomatic to IC to CLI can be observed but is not typical, as more than 50% of patients 
undergoing amputation were symptom free six months earlier [3, 15]. Patients presenting 
with CLI have the worse prognosis, with 12% requiring amputation within 3 months, and 
a 40-70% mortality rate at five years after presentation [3, 15]. 
 
2.1.5: Current Therapies and Limitations 
The standard treatment for PAD depends on the clinical presentation. For patients with 
IC, clinical interventions can be classified as risk factor control, pharmacological therapy, 
and surgical or catheter based interventions [5, 13, 14]. Risk factor control includes 
smoking cessation, weight loss, reduction of HbA1c levels, and increase in exercise [13, 
14]. Cigarette smoking has been shown to have a negative impact on different risk factors 
for atherosclerotic disease, such as levels of triglycerides, low density lipoprotein 
cholesterol, high density lipoprotein cholesterol, and plasma fibrinogen [14]. Thus, 
smoking cessation leads to improvement in these risk factors and a decrease in the 
incidence and progression of PAD [13]. Weight loss has also been shown to improve risk 
factors associated with PAD, such as insulin resistance, dyslipidemia, and hypertension 
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[13]. For DM patients, a 1% increase HbA1c has been associated with a 26% increase in 
PAD risk [3, 13]. Thus, lifestyle modification, such as changes in diet and weight loss, 
along with pharmacological therapies should be considered in order to ensure HbA1c 
levels remain below 6-7% [13]. Finally, exercise has been linked with functional 
improvement in patients with IC through different proposed mechanisms, such as arterial 
collateralization, increased capillary density and permeability, increased vascular 
endothelial growth factor (VEGF) levels, increased release of nitric oxide caused by shear 
stress, reduced blood viscosity, increased mitochondrial function leading to enhanced 
oxygen extraction ratios, improved gait proficiency, reversal of metabolic myopathies, and 
decreased endothelial inflammation [14]. The appropriate exercise program depends on 
the clinical presentation of each individual patient [13, 14]. 
 
Pharmacological therapies for patients with IC can be divided into therapies that improve 
cardiovascular outcomes and therapies that provide symptomatic relief [14]. Medications 
that improve cardiovascular outcomes include antiplatelet agents, β-blockers, angiotensin 
converting enzymes, thiazides, and statin drugs [14, 15]. These drugs focus on controlling 
risk factors of PAD, such as hypertension and hyperlipidemia, and have been shown to 
reduce adverse cardiovascular events [14]. Medications that improve IC symptoms 
include cilostazol, pentoxifylline, and naftidrofuryl oxalate [14, 15]. Cilostazol has 
antiplatelet properties, increases vasodilation, increases plasma high density lipoprotein 
level and decreases triglyceride levels [5, 14]. In clinical studies, cilostazol has been 
shown to increase pain free walking distance by 65-83% after 24 weeks [5, 14]. 
Pentoxifylline improves red blood cell deformability, lowers fibrinogen levels, and inhibits 
platelet aggregation. However, the clinical benefit of pentoxifylline is undetermined and 
may not be different from placebo [5, 14]. Naftidrofuryl oxalate is believed to be a 
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vasoactive drug that offers modest improvement in walking distance with minimal side 
effects. However, there is little follow up data beyond six months and cost effectiveness 
remains questionable [15]. 
 
Finally, for IC patients with severe impairment in their occupational and leisure time 
capabilities, surgical or catheter based interventions can be considered [14, 15]. The goal 
of this intervention is to preserve and improve functional capacity and limb salvage [14, 
15]. These procedures are not common in patients with IC, and are usually reserved for 
patients with CLI [14, 15]. 
 
For patients with CLI, the same risk factor control and pharmacological therapies as those 
given to patients with IC are administered as complements to revascularization [3, 5, 29]. 
Revascularization can be classified as endovascular interventions, surgical interventions, 
or a combination of both [3, 5, 29]. Endovascular interventions include angioplasty and 
stents, with many new drug eluting balloons and stents currently being explored [15, 29]. 
Surgical interventions include bypass surgery with a single reversed or in situ saphenous 
vein or other conduits, such as spliced arm and leg veins or prosthetic 
polytetrafluorethylene [15, 29]. Some studies suggest that outcomes in patients that 
undergo endovascular interventions are similar to those that undergo surgical 
interventions with regards to 5 year amputation free survival and mortality, thus many 
patients receive endovascular interventions first, followed by surgical interventions if there 




Unfortunately, a significant number of PAD patients do not respond to pharmacologic 
therapies and are not suitable candidates for surgery due to comorbidities or unfavorable 
anatomy, leaving amputation as their only treatment option [4-6, 13, 15, 16]. The prognosis 
of PAD patients that undergo amputation does not significantly improve, with a 30-50% 
mortality rate within 2 years of surgery and quality of life indices similar to those of terminal 
cancer patients [6]. 
 
2.1.6: Therapeutic Angiogenesis 
New blood vessel formation, or neovascularization, is thought to be result of three distinct 
processes: angiogenesis, arteriogenesis, and vasculogenesis [5]. Angiogenesis refers to 
the sprouting of new capillaries from pre-existing ones, a process caused by hypoxia and 
mediated by hypoxia inducible factor (HIF)-1α and VEGF [5]. Arteriogenesis refers to the 
maturation of pre-existing collaterals or de novo formation of mature vessels capable of 
carrying significant blood flow. This process is caused by shear stress and inflammation 
and is mediated by invasion of immune cells and the production of fibroblast growth factors 
(FGFs) [5]. Vasculogenesis refers to in situ formation of blood vessels from endothelial 
progenitor cells (EPCs) [4, 5]. All three processes are active and work together to produce 
new blood vessels in adults [5]. 
 
For PAD patients that remain refractory to the standard pharmacologic and surgical 
treatments, one novel approach being investigated is known as therapeutic angiogenesis, 
in which pro-angiogenic signals are delivered into ischemic tissue in order to enhance 
collateral circulation and blood flow [4-6, 26]. These pro-angiogenic signals can be 
classified into cell-based therapies and growth-factor-based therapies. Despite promising 
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results in animal models and phase I/II clinical studies, no new therapies for PAD patients 
have been successfully developed [4-6, 19, 26, 27, 30]. 
 
2.1.6.1: Cell-Based Therapies 
Cell-based therapies have focused on the delivery of different stem cells to ischemic tissue 
in patients with PAD. Cells of interest include purified EPCs and EPC progenitor cells, 
such as bone marrow mononuclear cells and peripheral blood mononuclear cells. In 
different animal models, these cells have been shown to induce neovascularization [4-6]. 
In clinical studies, delivery of these cells has led to improvements in different end points 
such as vascularization, ulcer healing, and limb salvage. However, most of these studies 
enroll a low number of patients, have different clinical inclusion criteria, use different end 
points, and involve mostly case reports and pilot studies. Furthermore, significant adverse 
events such as worsening of lesions and development of arteriovenous shunts were 
reported [4]. It is also not clear which cell types should be used, which markers should be 
used to define these cells, what cell source to use in order to avoid immunogenic rejection, 
what number of cells should be administered due to low retention rates, what the 
mechanisms of action of these cells are, or what the long-term effects of these cells are 
[4-6, 27]. One mechanism proposed suggests that these cells exert their angiogenic effect 
through the secretion of different growth factors such as VEGF instead of through their 
incorporation into ischemic tissue, which has led to the development of different growth-
factor-based therapies [4, 6, 19]. 
 
2.1.6.2: Growth-Factor-Based Therapies 
Growth-factor-based therapies have focused on the delivery of growth factors to ischemic 
tissue using gene therapy or direct delivery of recombinant proteins. Several different pro-
angiogenic growth factors have been studied, including VEGF, acidic FGF (FGF-1), basic 
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FGF (FGF-2), hepatocyte growth factor (HGF), and HIF-1 [4, 5, 31]. These growth factors 
have shown increases in blood vessel formation and myocyte regeneration when 
delivered as either gene therapy or recombinant proteins in different animal models [4, 7, 
26, 27, 32, 33]. Despite their apparent safety in phase I/II clinical trials, several concerns 
remain regarding the systemic distribution of growth factors. For example, delivery of 
growth factors can lead to plaque growth and destabilization in patients with 
atherosclerotic disease, leading to thrombus formation and adverse cardiovascular 
events. The presence of growth factors in orbital fluid can also lead to the development of 
proliferative retinopathy. Finally, the presence of growth factors can lead to accelerated 
tumor growth or metastasis [4, 5]. Interestingly, one of the proposed mechanism of action 
of growth factors such as VEGF and stromal cell derived factor-1 (SDF-1) is their 
involvement in EPC recruitment, retention, and differentiation at the site of injury, 
suggesting there is a close relationship between cell-based therapies and growth-factor 
based therapies [4]. 
 
3.1.6.2.1: Gene Therapy 
Gene therapy techniques involve the delivery of plasmid DNA or replication-defective 
adenovirus containing the gene of interest [4, 5]. Although other viral vectors have been 
utilized for gene therapy, such as adeno-associated virus and lentiviral vectors, these 
vectors integrate into the host genome and there are concerns regarding their safety [5]. 
Phase I/II clinical trials using different gene therapy techniques have shown conflicting 
results. For example, one clinical trial using a plasmid encoding human VEGF suggested 
an improvement in different endpoints such as ulcer healing and rest pain, and showed 
the development of new collateral vessels. However, a different clinical trial using a similar 
plasmid encoding human VEGF showed no decrease in amputation events [4]. This 
variability is probably due to the low number of patients in each study, different clinical 
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criteria for each study, and the different end points used for each study [4]. Furthermore, 
some clinical studies reported adverse events such as the development of local, 
moderate, or severe edema and the development of spider angiomas [4, 6]. There are 
also concerns about the poor efficiency of gene transfer, the variability in the level and 
duration of the gene expression among patients, the patient’s immune and/or inflammatory 
response against viral vectors, and the numerous potential side effects caused by 
systemic distribution of the gene [4, 6-8]. 
 
2.1.6.2.2: Recombinant Proteins  
Delivery of angiogenic recombinant proteins can done systemically, intra-arterially or via 
direct intramuscular (IM) injection [5]. Phase I/II clinical trials using recombinant proteins 
have shown mixed results. A clinical trial in which recombinant FGF-2 was delivered to 
patients with IC showed increases in peak walking time compared to placebos; however, 
no functional improvements in activities of daily living or quality of life were observed [6, 
31]. When compared to gene therapy, recombinant proteins offer better temporal control, 
more defined dosing, and no inflammatory response compared to gene therapy. However, 
there are concerns over the protein’s short half-life, inadequate retention at target tissue, 
inadequate delivery, and numerous systemic side effects [5, 7, 8, 19, 26, 33-35]. 
 
2.1.6.2.3: Bioengineered Approaches for Protein Delivery 
To address the limitations of direct recombinant protein administration, new techniques 
that provide localized, sustained delivery of protein to ischemic tissue have been 
developed. For example, VEGF has been packed in different nanoparticles and 
biodegradable polymers and shown promising results in different animal models of 
cardiovascular disease [19, 27, 36-40]. However, the current processing conditions to 
make these polymers can reduce the bioactivity of recombinant proteins such as VEGF 
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[41], and the delivery of some polymers and nanoparticles requires either catheterization 
of the unaffected femoral artery or invasive surgical implantation within ischemic tissue. 
Although feasible, these invasive techniques are less favored than an IM or intravenous 
(IV) injection [19, 26, 41-44]. 
 
2.2: Vascular Endothelial Growth Factor 
 
The VEGF family is a family of glycoproteins that includes VEGF-1 (VEGF-A), VEGF-2 
(VEGF-C), VEGF-3 (VEGF-B), VEGF-D, VEGF-E, and placental growth factor (PGF) [5, 
45]. Of these, the most potent and best characterized proangiogenic factor is VEGF-1, 
which contains at least four different isoforms of different amino acid length: VEGF121, 
VEGF165, VEGF189, and VEGF206 [4, 5, 26, 46]. VEGF121 and VEGF165 are secreted as 
soluble factors into the extracellular space, while VEGF189 and VEGF206 are secreted but 
remain cell or matrix associated [5, 46]. Both of the secreted isoforms have similar 
angiogenic and mitogenic potency, but VEGF165 is more predominant and retains its 
heparan sulfate and heparin binding capacity [4, 45, 46]. 
 
Ligands in the VEGF family bind to three different tyrosine kinase receptors: 1) Flt-1 
(VEGFR-1), 2) KDR/Flk-1 (VEGFR-2), and 3) Flt-4 (VEGFR-3) [5, 45]. VEGFR-2 is 
thought to transduce angiogenic signals and is predominantly found on vascular ECs and 
their embryonic precursors [5]. VEGFR-2 has several phosphorylation sites, and activation 
of VEGFR-2 by its ligand induces EC survival, proliferation and migration in vitro, and it 
leads to an increase in vascular permeability and the formation of vascular tubes (i.e.: 
angiogenesis) in vivo [33, 45, 46]. Many different proteins and pathways are involved in 
these processes. For example, phosphorylation of Tyrosine1175 has been linked to the 
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activation of the protein kinase C [45, 47], which in turn activates the ERK1/2 pathway and 
leads proliferation of ECs [45, 48] 
 
Structurally, VEGFs are generally homodimeric peptides stabilized into its quaternary 
structure through different disulfide bonds [45, 46]. The 8 different cysteine residues that 
are involved in intra- and inter-chain disulfide bonds are conserved among the different 
VEGF isomers [46]. Of particular interest for this project, VEGF165 contains an additional 





Hoechst is a fluorescent molecule that has high affinity (~60nM) and high specificity for 
the A-T rich sequences of double stranded DNA [21, 23, 49]. Hoechst is biocompatible in 
humans [23, 50, 51], and it has been previously modified at its terminal phenol without 
losing its ability to bind with DNA [21, 23]. The incorporation of a polyethylene glycol (PEG) 
linker has been used to increase the compound’s hydrophilicity and prevent it from 





Cardiomyopathy and myocarditis are an increasing global medical problem, particularly in 
the pediatric population [52]. Due to heterogeneous clinical presentation, patient cases of 
myocarditis are believe to be significantly underestimated [53]. In the United States, the 
incidence of cardiomyopathy in infants less than 1 year of age is estimated to be 8.34 
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cases per 100,000 [1]. The most common form of cardiomyopathy in children is dilated 
cardiomyopathy (DCM), with an estimated annual incidence in infants less than 1 year of 
age of 4.40 cases per 100,000 [1]. Although the cause of DCM remains unidentified in 
66% of cases, myocarditis accounts for 46% of the known causes [1, 52]. Globally, the 
prevalence of myocarditis is estimated to be about 22 per 100,000 patients, with the 
number of deaths attributed to cardiomyopathy and myocarditis increasing by 40.8% 
between 1990 and 2010 (from 286,800 to 403,900), even though the age standardized 
death rate decreased by 9.8% (from 6.7 to 6.1 deaths per 100,000) [1, 53]. In adolescents 
and young adults, myocarditis is implicated in 12% of sudden cardiac deaths [12]. In 
adults, myocarditis ranks as the third leading cause of sudden cardiac death in competitive 
athletes [53]. Myocarditis is also associated with significant morbidity. It accounts for ~11% 
of heart failure cases, and it is the most common cause for heart transplantation worldwide 
due to the lack of appropriate diagnostics and treatments [54]. 
 
2.4.2: Pathophysiology 
Myocarditis refers to localized or diffuse inflammation of the myocardium [9-11]. It is a 
complex disease that can be caused by infections (bacterial, rickettsial, mycotic, 
protozoan, and viral agents), cardiotoxic agents (drugs, toxins, and alcohol), or 
autoimmune disease, but many cases remain idiopathic [9, 11, 12, 54-59]. Although the 
exact mechanisms through which myocarditis develops are not well understood for most 
of these causing agents, evidence suggests that myocarditis is mediated by the direct 
injury of the causing agent and the indirect injury of the innate and adaptive immune 
systems of the host [10, 12, 53, 54].  
 
The development of myocarditis after coxsackie B3 Virus infection has been extensively 
studied in both animal and tissue cultures cells [11, 53]. In this model, three different 
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phases can be observed [11, 12, 53, 54, 56]. In the first phase, the virus infects 
cardiomyocytes, replicates, and induces the destruction of cardiomyocytes [11, 58]. Viral 
proteases are involved in both inducing apoptosis and enhancing proteolytic activity and 
necrosis in cardiomyocytes [11, 12, 56, 57]. The innate immune system is activated, and 
an invasion of natural killer cells and macrophages followed by T lymphocytes is observed 
[12, 53, 57]. During this phase, the innate immune system is activated through different 
mechanisms including pro-inflammatory cytokines, suppressors of cytokine signaling 
proteins, and Toll-like receptors (TLRs) [11, 54]. TLRs are able to recognize damage 
associated molecular patterns (DAMPs) and pathogen-associated molecular patterns 
(PAMPs), which may enhance cardiac cell injury or result in the efficient clearance of the 
virus (i.e.: asymptomatic myocarditis) [11]. This acute phase lasts a few days [56, 57]. In 
the second phase, the presence of the viral genome even in the absence of viral replication 
leads to immune dysregulation, which is characterized by maintenance of an immune 
response with continuous injury to the heart [11]. The adaptive immune system is 
activated, and autoimmune reactions develop, mediated by viral specific T-cells targeting 
host myocytes by molecular mimicry, as well as by cytokines and antibodies to both viral 
and cardiac proteins [56-58]. This second phase last weeks to months, resulting in either 
the pathogen being cleared or the continuation of an autoimmune process [56, 57]. In the 
third phase, the presence of circulating cross reacting autoantibodies in addition to the 
virus-induced cardiomyocyte injury and the resulting release of cytokines leads to 
remodeling of the heart and the development of DCM [11, 12, 53, 56-58]. 
 
2.4.3: Clinical Presentation 
The clinical presentation of patients with myocarditis tends to be heterogeneous, but it can 
be divided based on different cluster of symptoms observed: asymptomatic, acute 
coronary syndromes (ACS-like), new-onset heart failure, life threatening arrhythmias, and 
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chronic heart failure [9, 12, 55]. The signs and symptoms of these clinical presentations 
are not specific to myocarditis. For patients presenting with ACS-like symptoms, 
myocarditis is often hard to differentiate from acute myocardial infarction (AMI) [9]. In fact, 
even when coronary angiography studies reveal patent coronary arteries, AMI secondary 
to vasospasm or embolism is assumed instead of myocarditis [9]. For patients presenting 
with new onset heart failure, myocarditis is assumed only when other causes, such as 
ischemic or valvular heart disease, are excluded [9]. Myocarditis patients can also present 
with a wide range of life threatening arrhythmias, including atrioventricular blocks, 
ventricular fibrillation/flutters, and sustained ventricular tachycardia [9]. However, 
myocarditis is only suspected in these patients in the absence of coronary artery disease 
or other electrophysiological abnormalities. Finally, although myocarditis induced DCM is 
one of the main causes of heart failure, they are various other causes of DCM, and in 66% 
of the cases the cause remains unidentified [1, 9]. Further complicating the clinical picture, 
pediatric patients often present with nonspecific symptoms, and infants in particular are 
often unable to verbalize what these symptoms are [12, 56, 59]. 
 
2.4.4: Other Classifications 
Beyond the wide range of etiologies and heterogeneous clinical presentation, myocarditis 
can also be classified based on different parameters such as symptom onset and 
histological findings [9, 53]. Based on symptom onset, myocarditis can be classified as 
fulminant, acute or chronic. Chronic myocarditis can be further subdivided based on the 
level of inflammation: persistent inflammation, chronic viral infection (with or without 
inflammation), and healed inflammation (with or without irreversible damage to the heart) 




The infiltration of immune cells in myocarditis can be either diffuse or focal [53]. Based on 
the type of infiltrative cells observed on histological samples, myocarditis can be classified 
into lymphocytic, giant cell, granulomatous, eosinophilic and neutrophilic myocarditis [9]. 
Lymphocytic myocarditis is the most commonly observed [55]. Giant cell myocarditis is 
characterized by the presence of multinucleated giant cells, with an autoimmune response 
being the probable cause [53, 55]. Giant cell myocarditis is also one of the most rapidly 
progressing forms of myocarditis [55]. Eosinophilic myocarditis is characterized by 
eosinophilic infiltrate and is sometimes referred to as hypersensitivity myocarditis [53, 55]. 
It has an acute onset, rapid progression, and extensive necrosis, which is why it is also 
sometimes referred to as necrotizing eosinophilic myocarditis [53, 55]. 
 
2.4.5: Current Therapies and Limitations 
The cornerstone therapy of myocarditis is supportive therapy and symptomatic relief, as 
many myocarditis patients will eventually recover with little or no cardiac consequences 
[9, 12, 56]. The supportive therapy of choice depends on the clinical presentation, and it 
includes diuretics, inotropes, afterload reduction agents, β blockers, and antidysrhythmics 
[12, 56]. For patients with life threatening arrhythmias, the placement of a pacemaker or 
defibrillator may be necessary [12, 56]. For patients with new-onset heart failure and 
chronic heart failure that fail to improve, extracorporeal membrane oxygenation and long 
term ventricular assist devices may be options [12, 56]. For some patients, the cardiac 
damage and function impairment may be so extensive as to require heart transplantation, 
which is particularly true in patients presenting with DCM [53, 56]. 
 
The use of immunosuppressive agents has been met with mixed results, as most clinical 
evidence is based on small clinical studies with a wide range of clinical inclusion criteria 
[9, 53, 56]. In general, immunosuppressive therapy seems to benefit chronic patients but 
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not acute patients [53], although some argue that autoimmune therapy is only beneficial 
in autoimmune mediated myocarditis and can even be detrimental in viral myocarditis [9]. 
 
The use of antivirals and antibiotics is recommended only when treatable causes of 
myocarditis can be identified [56]. For example, patients with myocarditis associated with 
Epstein-Barr virus and varicella virus have been reported to benefit from the use of 
acyclovir [56]. Similarly, phase II clinical trials have demonstrated that IV delivery of 
Interferon-β eliminates the viral load and improves clinical symptoms of myocarditis [54]. 
Despite these promising results, the use of antivirals and antibiotics is limited by 
nonspecific targeting, unclear mechanisms, and numerous side effects [53]. 
 
2.4.6: Current Diagnosis and Limitations 
The heterogeneous etiology, pathophysiology, and clinical presentation of myocarditis 
makes it one of the most challenging diagnosis in cardiology and leads to the under-
diagnosis of cases of myocarditis [9, 12]. Patients suspected of myocarditis will undergo 
many different diagnostic tests, including electrocardiography (EKG), chest radiography, 
and echocardiography [56]. However, the two diagnostic modalities with the greatest 
sensitivity for myocarditis are endomyocardial biopsy (EMB) and cardiac magnetic 
resonance (CMR) imaging [9]. 
 
2.4.6.1: Endomyocardial Biopsy 
The gold standard for the diagnosis of myocarditis is EMB, complemented by 
immunohistochemistry and PCR [9, 11, 12, 53, 55-57, 60]. This procedure provides 
information about the presence of viral genome, fibrosis, cell death, the type of 
inflammatory infiltration, and the deposition of iron proteins or lipids [9, 59]. The procedure 
is considered to be safe when performed by experienced physicians; however, it is an 
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invasive procedure that has some risk of serious complications, particularly in children 
with rates as high as 10.6% [9, 12, 57, 59, 61]. These complications include cardiac 
perforation with tamponade, ventricular or supraventricular arrhythmias, heart block, 
pneumothorax, hemothorax, puncture of central arteries, pulmonary embolization, venous 
hematoma, damage to the tricuspid valve, stroke, and death [9, 12, 55, 57, 61]. 
Furthermore, studies that compared the performance of EMB to the ex vivo evaluation of 
hearts with myocarditis found that EMB misses approximately half of the diagnoses, even 
when 10 biopsy samples were analyzed [9]. Due to the diffuse nature of myocarditis, it is 
estimated that 17 biopsies are needed to reach a sensitivity of only 80% [9, 57], and thus 
there is a decreased reliance on EMB particularly in pediatric populations in the United 
States [56-58]. The type of infiltrative cells observed in patients with myocarditis also 
seems to play a role in the sensitivity of EBM, with low sensitivities corresponding to 
lymphocytic myocarditis and high sensitivities (80-85%) corresponding to giant cell 
myocarditis or eosinophilic myocarditis [55]. 
 
2.4.6.2: Cardiac Magnetic Resonance 
CMR is a non-invasive imaging modality that allows us to assess the structure and function 
of the heart [9]. It can be used to demonstrate typical features of acute myocarditis such 
as dysfunction, edema and necrosis [9, 53, 56, 57, 59, 60]. The use of contrast agents, 
such as gadolinium based contrast agent, can provide enhanced signal, particularly in 
regions of necrosis or fibrosis as a result of myocarditis [9, 12, 53, 59]. Studies that 
compared the performance of CMR to biopsy samples reported sensitivities between 47% 
and 74% depending on the modality used [9]. Despite improvements in the diagnostic 
criteria used with CMR, the diagnosis of a substantial number of patients may still be 
missed, particularly in patients in the chronic phase of myocarditis [9, 60]. Furthermore, 
CMR cannot be used to determine the underlying cause of myocarditis, to stratify the risk 
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of different patients, and the findings have not yet been validated in pediatric patients [9, 
56, 57]. 
 
2.4.6.3: Other Diagnostic Studies 
Patients with myocarditis will present with different abnormalities in various different 
imaging studies. Between 93-100% of patients with myocarditis will present some sort of 
abnormality on EKG, between 60-90% will also present with some sort of abnormality on 
chest radiography, and many of them will also present with left ventricular or biventricular 
dysfunction on echocardiography [12, 56]. These imaging modalities can be used for risk 
stratification, initial screening, or to eliminate other underlying causes, but they have low 
diagnostic value, low sensitivity, and do not provide direct evidence for a diagnosis of 
myocarditis [53, 56]. Troponin levels and inflammatory markers such as white blood cell 
count, C-reactive protein, and erythrocyte sedimentation rate, are usually elevated in 
patients with myocarditis, but these tests lack the sensitivity and specificity necessary to 
diagnose myocarditis and may be elevated due to other underlying causes such AMI [56]. 
Finally, Microbiological studies have very low diagnostic yields, but samples should be 
obtained early in patients suspected of myocarditis [56]. 
 
2.4.6.4: Diagnostic Approach 
Patients clinically suspected of myocarditis will undergo different evaluations including 
EKG, chest radiography, troponin levels, inflammatory markers, and echocardiography, 
which will eliminate other causes of cardiac clinical symptoms and provide insight as to 
the risk of myocarditis [9, 56]. Patients still suspected of myocarditis should always be 
evaluated with CMR when possible [9]. EMB should be required in all patients that are 
hemodynamically unstable in order to differentiate between viral and autoimmune disease 
and inform on the use of immunosuppressive therapy [9]. EMB should also be considered 
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in all patients with new onset heart failure and life threatening arrhythmias whose clinical 
presentation fails to improve [9]. EMB should not be performed on patients with ACS-like 
presentation, as these patients tend to have excellent prognosis [9]. 
 
2.4.7: Targeted Molecular Imaging 
Due to the low diagnostic value, sensitivity, and specificity of current imaging techniques 
[9, 53, 56, 57, 60], modifications to these imaging techniques that allow for the targeted 
molecular imaging of myocarditis are currently being explored. For example, targeted 
molecular imaging using fluorine-19 in CMR has been shown to detect myocardial 
inflammation in an animal model of experimental autoimmune myocarditis (EAM) through 
the incorporation of fluorine-19 into macrophages, dendritic cells, and granulocytes [62]. 
However, fluoride-19 is not specific to myocarditis and can be incorporated by 
macrophages and monocytes in other disease processes such as pneumonia, allograft 
rejection, cardiac ischemia, and cerebral ischemia [62]. Similarly, microbubbles with 
modifications or coated with antibodies targeting leukocytes, endothelial cells, and T-
lymphocytes were shown to enhance ultrasound signal in animals with EAM; however, the 
use of antibodies in therapies is limited by production costs, low tissue penetration, and 




CHAPTER 3: TARGETED DELIVERY OF VASCULAR ENDOTHELIAL GROWTH 




3.1.1: Peripheral Artery Disease 
Peripheral artery disease (PAD) affects between 8-10 million people in the United States, 
and it is associated with significant morbidity and mortality. In 2011, PAD any mention 
mortality in the United States was 62,183 people (age-adjusted death rate of 18.1 per 
100,000 people), with PAD being the underlying cause of 13,484 of those deaths [1]. 
Patients with PAD report impaired function and quality of life, which is true even in patients 
that are currently asymptomatic [1]. It estimated that $4.37 billion are spent every year in 
the treatment and management of PAD, with most expenditures associated with repeated 
hospitalizations and surgical procedures [14]. 
 
PAD is characterized by the occlusion of peripheral arteries caused mainly by 
atherosclerosis and associated thrombosis [3, 5, 16-18]. The body responds to this 
gradually progressive limb ischemia by increasing blood flow through the promotion of 
angiogenesis and arteriogenesis [3]. In patients with the more severe critical limb ischemia 
(CLI), these processes become ineffective, which leads to an on-going inadequate 
perfusion of tissue, depriving myocytes of oxygen and other nutrients [3, 4]. Within hours, 
these cells become either apoptotic and/or terminally necrotic, losing the ability to be 
rescued even with reperfusion therapy [19-21]. During necrosis, the membrane integrity 
of these necrotic myocytes becomes compromised, resulting in the release of cellular 
contents, including DNA, into extracellular space [21-23]. Myocyte necrosis, depending on 
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its extent, may lead to impaired healing, decreased muscle mass, disease progression, 
and loss of normal muscle function, causing significant morbidity and mortality [1, 26, 27] 
 
The standard treatment for PAD depends on the clinical presentation. For patients with 
the less severe intermittent claudication (IC), clinical interventions include risk factor 
control (smoking cessation, weight loss, reduction of hemoglobin A1c levels, and increase 
in exercise), pharmacological therapy (antiplatelet agents, β-blockers, angiotensin 
converting enzymes, thiazides, and statin drugs, cilostazol, pentoxifylline, and naftidrofuryl 
oxalate), and in some cases surgical or catheter based interventions [5, 13-15]. For 
patients with CLI, risk factor control and pharmacological therapies are administered as 
complements to revascularization, which can be done through endovascular interventions, 
surgical interventions, or a combination of both [3, 5, 29]. Unfortunately, a significant 
number of PAD patients do not respond to pharmacologic therapies and are not suitable 
candidates for surgery due to comorbidities or unfavorable anatomy, leaving amputation 
as their only treatment option [4-6, 13, 15, 16]. The prognosis of PAD patients that undergo 
amputation does not significantly improve, with a 30-50% mortality rate within 2 years of 
surgery and quality of life indices similar to those of terminal cancer patients [6]. 
 
3.1.2: Therapeutic Angiogenesis 
For PAD patients that remain refractory to the standard pharmacologic and surgical 
treatments, one novel approach being investigated is known as therapeutic angiogenesis, 
in which pro-angiogenic signals are delivered into ischemic tissue in order to enhance 
collateral circulation and blood flow [4-6, 26]. These pro-angiogenic signals can be 
classified into cell-based therapies and growth-factor-based therapies. Despite promising 
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results in animal models and phase I/II clinical studies, no new therapies for PAD patients 
have been successfully developed [4-6, 19, 26, 27, 30]. 
 
Cell-based therapies have focused on the delivery of purified endothelial progenitor cells 
(EPCs) and EPC progenitor cells to ischemic tissue in patients with PAD. Animal and 
clinical studies have shown these cells can induce angiogenesis and symptomatic 
improvement [4-6]. Despite these promising results, many questions remain, such as 
which cell types to use, which markers to use to define these cells, what cell source to use 
to avoid immunogenic rejection, what number of cells to administer due to low retention 
rates, what are the mechanisms of action of these cells, or what are the long-term effects 
of these cells [4-6, 27]. One mechanism proposed suggests that these cells exert their 
angiogenic effect through the secretion of different growth factors, such as vascular 
endothelial growth factor (VEGF), instead of through their incorporation into ischemic 
tissue, which has led to the development of different growth-factor-based therapies [4, 6, 
19]. 
 
Growth-factor-based therapies have focused on the delivery of growth factors to ischemic 
tissue using gene therapy or direct delivery of recombinant proteins. Several different pro-
angiogenic growth factors have been studied, including VEGF, acidic fibroblast growth 
factor (FGF-1), basic fibroblast growth factor (FGF-2), hepatocyte growth factor (HGF), 
and hypoxia inducible factor (HIF)-1 [4, 5, 31]. These growth factors have induced 
angiogenesis and myocyte regeneration when delivered as either gene therapy or 
recombinant proteins in different animal models [4, 7, 26, 27, 32, 33]. Furthermore, 
different phase I/II clinical studies have shown the safety of these approaches [4-6, 31]. 
Despite these results, several concerns remain regarding the systemic distribution of 
growth factors, such as the promotion of plaque growth and destabilization in patients with 
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atherosclerotic disease, the development of proliferative retinopathy, or the acceleration 
of tumor growth or metastasis [4, 5]. Specific to gene based therapies, there are also 
concerns about the poor efficiency of gene transfer, the variability in the level and duration 
of the gene expression among patients, and the patient’s immune and/or inflammatory 
response against viral vectors [4, 6-8]. In contrast to gene therapy, recombinant proteins 
offer better temporal control, more defined dosing, and no inflammatory response; 
however, there are concerns over the protein’s short half-life, inadequate retention at 
target tissue, and inadequate delivery to target tissue [5, 7, 8, 19, 26, 33-35]. 
 
To address the limitations of direct recombinant protein administration, new techniques 
that provide localized, sustained delivery of protein to ischemic tissue have been 
developed. For example, VEGF has been packed in different nanoparticles and 
biodegradable polymers and shown promising results in different animal models of 
cardiovascular disease [19, 27, 36-40]. However, the current processing conditions to 
make these polymers can reduce the bioactivity of recombinant proteins such as VEGF 
[41], and the delivery of some polymers and nanoparticles requires either catheterization 
or invasive surgical implantation within the ischemic tissue. Although feasible, these 
invasive techniques are less favored than an intramuscular (IM) or intravenous (IV) 
injection [19, 26, 41-44]. 
 
3.1.3: Vascular Endothelial Growth Factor  
One of the most potent and best characterized pro-angiogenic factors is VEGF-1 [4, 5, 26, 
45, 46]. Alternative splicing of VEGF-1 leads to the production of different isoforms, of 
which only VEGF121 and VEGF165 are secreted as soluble factors into extracellular space 
[4, 5, 26, 46]. Both of these secreted isoforms have similar angiogenic and mitogenic 
potency, but VEGF165 is more predominant and retains its heparan sulfate and heparin 
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binding capacity [4, 45, 46]. Structurally, VEGFs are generally homodimeric peptides 
stabilized into its quaternary structure through different disulfide bonds [45, 46]. The 8 
different cysteine residues that are involved in intra- and inter-chain disulfide bonds are 
conserved among the different VEGF isomers, including VEGF121 and VEGF165 [46]. Of 
particular interest for this project, VEGF165 contains an additional 8 free cysteine residues 
that are not involved in disulfide bonds while VEGF121 does not contain any. 
 
It has been suggested that the use of shorter bioactive peptide sequences derived from 
growth factor proteins could be advantageous in certain applications, as long as these 
peptides retain the same bioactivity [65]. For VEGF, a mimetic peptide (QK, Sequence: 
Ac-KLTWQELYQLKYKGI-amide) that offers lower molecular and biological complexity 
than VEGF165, but retains VEGF165’s angiogenic activity has been previously developed 
and tested both in vitro and in vivo [65-67]. This peptide is easier to manipulate, and it only 
interacts with its specific VEGF Receptor (VEGR)-2, thus avoiding any off target effects 
that VEGF165 might have [67]. 
 
Ligands in the VEGF family bind to three different tyrosine kinase receptors: 1) Flt-1 
(VEGFR-1), 2) KDR/Flk-1 (VEGFR-2), and 3) Flt-4 (VEGFR-3) [5, 45]. VEGFR-2 is 
thought to transduce angiogenic signals and is predominantly found on vascular 
endothelial cells and their embryonic precursors [5]. Activation of VEGFR-2 by its ligand 
induces EC survival, proliferation and migration in vitro, and it leads to an increase in 






Hoechst is a fluorescent molecule that has nanomolar affinity for the A-T rich sequences 
of double stranded DNA [49, 68]. Hoechst is biocompatible in humans [50, 51], and it has 
been previously modified without losing its ability to bind with DNA [23, 68]. In previous 
studies, a modified Hoechst has been used to deliver Insulin Growth Factor (IGF)-1 to 
necrotic tissue in an animal model of myocardial infarction by binding to extracellular DNA 
[23]. Thus, a modified Hoechst should also bind to the high concentrations of DNA 
released into extracellular space by necrotic tissue in PAD [68]. 
 
3.1.5: Approach 
We developed a novel delivery system in which a modified Hoechst compound can be 
used to deliver either a VEGF mimetic peptide (VEGFmp) or VEGF165 to the necrotic tissue 
in PAD. We hypothesized that both of our compounds, Hoechst-VEGFmp (HoVEGFmp) 
or Hoechst-VEGF165 (HoVEGF165), would be retained in and/or target necrotic tissue in 
animal model of PAD. This approach could enhance the pro-angiogenic effects of VEGF 
therapy, reduce its side effects, and lead to improved clinical outcomes in PAD patients. 
 
3.2: Methods and Results 
 
3.2.1: Synthesis of Hoechst Compounds 
We modified Hoechst by adding a polyethylene glycol (PEG) chain that will render the 
compound cell impermeable, ensuring it will only target extracellular DNA released by 
necrotic cells [21, 23]. Furthermore, a thiopyridyl moiety was attached to the PEG chain in 
order to permit the cysteine-specific incorporation of this compound to recombinant 





Figure 1: Schematic of Hoechst-thiopyridyl. A modified Hoechst derivative, Hoechst-
thiopyridyl, was synthesized by adding a PEG linker (in black) and thiopyridyl moiety (in 
red) to Hoechst (in blue). 
 
3.2.1.1: HoVEGFmp 
We used the VEGF mimetic peptide (QK, Sequence: Ac-KLTWQELYQLKYKGI-amide 
[66]) due to its lower molecular and biological complexity, and the ability to easily modify 
it [65-67]. We performed two modifications on the sequence of this peptide: 1) an extra 
cysteine residue was added on the C terminus of the peptide to facilitate its conjugation 
with Hoechst-thiopyridyl, and 2) a fluorescent dye (HiLyte FluorT 647 or HiLyte Fluor 750, 
Anaspec) that is detectable at low concentrations (<150nM) [70] was added to the N 
terminus for in vivo and ex vivo imaging studies. The resulting VEGF mimetic peptide 
(VEGFmp, Sequence: Ac-CKLTWQELYQLKYKGIK[HiLyte FluorT 647]-NH2 or Ac-
CKLTWQELYQLKYKGIK[HiLyte Fluor 750]-NH2, Anaspec) was then conjugated with 
Hoechst-thiopyridyl through the formation of a single disulfide bond with the cysteine 
residue, and the resulting Hoechst-thiopyridyl-VEGFmp (HoVEGFmp) compound was 
dialyzed using a 2kDa molecular weight cutoff to remove any excess Hoechst-thiopyridyl 




The VEGF165 isoform was used due to the 8 free cysteine residues that are available to 
create a disulfide bond with the Hoechst-thiopyridyl derivative [46]. Before conjugation 
with Hoechst, VEGF165 was conjugated with an amine-reactive near-IR fluorescent dye 
(DyLight 800, Thermo Scientific #53063) that reacts with lysine residues to form stable 
amide bonds. The resulting VEGF165-DyLight 800 (VEGF165-Dy) was conjugated with 
Hoechst-thiopyridyl, and the resulting Hoechst-thiopyridyl-VEGF165-DyLight 800 
(HoVEGF165) was dialyzed using a 2kDa molecular weight cutoff to remove any excess 
Hoechst thiopyridyl (MW=751.96Da) in the solution. 
 
3.2.2: Bioactivity of Hoechst Compounds 
 
3.2.2.1: HoVEGFmp 
To determine if HoVEGFmp is a good therapeutic candidate for in vivo experiments, we 
evaluated the DNA binding activity and VEGF binding activity of HoVEGFmp in vitro.  
 
3.2.2.1.1: In Vitro Assessment of DNA Binding Activity 
Cardiomyocyte progenitor cells (CPCs) were treated with methanol (fixed) or standard 
tissue culture media (live) for 10 minutes. Both fixed and live cells received 2x10-6M of 
either Hoechst-thiopyridyl or HoVEGFmp. The treatment is two times the suggested dose 
[66], which was done with the intent of ensuring that DNA binding would be observable in 
this assay. As shown in Figure 2, both HoVEGFmp and Hoechst-thiopyridyl clearly bound 
to DNA found in the nucleus of fixed cells with compromised cell membranes. In contrast, 
no Hoechst-thiopyridyl or HoVEGFmp was able to bind to intracellular DNA of live cells 





Figure 2: Representative images of CPCs incubated with Hoechst compounds. CPCs 
were either fixed with methanol for 10 minutes or left untreated, followed by treatment for 
20 minutes with either Hoechst-thiopyridyl or HoVEGFmp. Fluorescent imaging: 40x, Blue: 
DAPI. 
 
3.2.2.1.2: In Vitro Assessment of Angiogenic Activity 
Immortalized mouse aortic endothelial cells (iMAECs), which express VEGFR-2, were 
treated with 1x10-6M of VEGFmp or HoVEGFmp for 1, 5, 10 or 30 minutes. After treatment, 
cells were lysed and western blot analysis was performed using phosphorylated and total 
ERK 1/2 antibodies. Figure 3A shows a representative image of the Western blot 
membrane that was obtained. Quantification of Western blots (Figure 3B) showed that the 
largest increase in the phosphorylation of ERK1/2 occurred after 1 and 5 minutes of 






Figure 3: Western blot analysis of iMAECs treated with VEGFmp compounds. After 
starving iMAECs for 5-6 hours, cells were treated with either VEGFmp or HoVEGFmp for 
1, 5, 10, or 30 minutes. Western blot analysis with pERK1/2 and total ERK1/2 antibodies 
was performed. (A) Representative image of Western blots. (B) Quantification of Western 
blots normalized to control (black line). (B) Two-way ANOVA not significant. Bars 
represent Mean ± SEM, n=2. 
 
3.2.2.2: HoVEGF165 
To determine if HoVEGF165 is a good therapeutic candidate for in vivo experiments, we 




3.2.2.2.1: In Vitro Assessment of DNA Binding Activity 
Similar to the experiments with HoVEGFmp, iMAECs were treated with methanol (fixed) 
or standard tissue culture media (live) for 10 minutes. Both fixed and live cells received 
2000ng/mL of Hoechst 33258, 2000ng/mL of Hoechst-thiopyridyl, or 500ng/mL of 
HoVEGF165. The treatment is in excess of the suggested dose [66], and the differences in 
dosage with the HoVEGF165 was due to limitations with the amount of compound available 
at the time. As shown in Figure 4, all three treatment groups successfully bound to DNA 
in the nucleus of fixed cells. In contrast, only Hoechst 33258 was able to bind to 
intracellular DNA of live cells with intact cell membranes. 
 
 
Figure 4: Representative images of iMAECs incubated with Hoechst compounds. iMAECs 
were either fixed with methanol for 10 minutes or left untreated, followed by treatment for 
20 minutes with either Hoechst 33258, Hoechst-thiopyridyl, or HoVEGF165. Fluorescent 
imaging: 20x, Blue: DAPI. 
 
3.2.2.2.2: In Vitro Assessment of Angiogenic Activity 
Rat cardiac endothelial cells (CECs) were treated with 500ng/mL of VEGF165, VEGF165-
Dy, or HoVEGF165 after being starved in low serum media for 24 hours. After 24 hours of 
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treatment, cells were re-plated on Geltrex coated plates at a density of 30,000 cells/cm2. 
Six hours after plating, the cells were treated with calcein green fluorescent dye and 
imaged. Figure 5 shows representative images obtained. All treatments led to tube 
formation. 
 
Figure 5: Representative images of CECs forming tubes. After starving Rat CECs 
overnight, cells were treated with HoVEGF165, VEGF165-Dy or VEGF165 for 24 hours. 
30,000 cells/cm2 were then plated on 96 well plates covered with Geltrex and allowed to 
form tubes for 6 hours. Fluorescent Imaging: 2x, Green: FITC. 
 
3.2.3: Animal Model of Peripheral Artery Disease 
We used a validated model of hindlimb ischemia (HLI) in male BALB/c mice, in which the 
femoral artery of one hindlimb was ligated at two different locations [26, 27, 38, 71-74] 
(Figure 6A). This model is reproducible and leads to the formation of large areas of 
necrotic tissue. Laser Doppler Perfusion Imaging (LDPI) was used to assess the success 
rate of the femoral ligation procedure by measuring the signal intensity of both the 
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ischemic and non-ischemic hindlimbs (Figure 6B). About 90% of animals tested in our 
preliminary studies had a perfusion ratio ≤ 0.2, indicating the procedure was successful. 
Any animal with an unsuccessful femoral ligation was excluded from our studies and 
immediately euthanized. 
 
Figure 6: Representative images of mouse model of HLI. Femoral ligation was performed 
at two different sites to induce ischemia. (A) Representative image of femoral ligation. (B) 
Representative image of LDPI performed 24 hours after femoral ligation. Black arrows 
represent the sites where the femoral artery was ligated, at the origin of the deep femoral 
artery and saphenous artery. 
 
The time course of DNA release following femoral artery ligation was measured. Briefly, 
C57BL/6 mice underwent one of three different surgical procedures: (1) femoral ligation 
(hindlimb ischemia model, HLI), (2) myocardial ischemia-reperfusion (myocardial 
infarction model, MI), or (3) no surgery (No Sx). Blood samples were obtained for each 
animal at 2, 24, and 48 hours after surgical procedure, and DNA concentration was 
measured using SYBR Gold Nucleic Assay Gel Stain and a plate reader [75]. As shown 
in Figure 7, DNA levels for both HLI and MI double by 24 hours after surgical procedure 
when compared to controls, although none of the differences observed between groups 
were statistically significantly. For all subsequent animal studies involving HLI, treatment 





Figure 7: DNA levels in the serum of C57BL/6 mice. C57BL/6 mice underwent different 
surgical procedures: Hindlimb Ischemia (HLI), Myocardial Infarction (MI) and No surgery 
(No Sx). DNA levels in serum were measured at 2, 24, and 48 hours after surgical 
procedure. Two-way ANOVA not significant. Points represent Mean ± SEM, n=2-4. 
 
3.2.4: Retention of Hoechst Compounds in Animal Model of PAD 
To determine the effectiveness of our targeted delivery approach, the retention of our 
compound was evaluated after an IM injection to ischemic tissue in a HLI model using 
BALB/c mice.  
 
3.2.4.1: HoVEGFmp 
The appropriate dosing was based on levels reported using a similar VEGF mimetic 
peptide (QK) dissolved into hydrogels to study this peptide’s angiogenic response when 
implanted into mouse corneas [65]. That study delivered 0.005nmol of peptide to each 
animal [65]. However, previous studies in our lab delivering a similar Hoechst-IGF-1 
compound IV to ischemic hearts have shown a targeting of 2-5% [23]. Thus, we chose to 
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start with a dose 50x higher than what was previously reported for peptide QK for our 
retention (IM) and targeting (IV) experiments [65]. 
BALB/c mice underwent femoral ligation followed by an IM injection of either VEGFmp or 
HoVEGFmp (55μL, 4.64µM, 1000ng, 0.255nmol total) 24 hours after surgery. Animals 
were imaged in vivo at 0 and 2 hours after treatment to determine the feasibility of in vivo 
fluorescent imaging with the Xenogen IVIS 100 imaging system. As shown in Figure 8, 
both VEGFmp and HoVEGFmp produced a detectable fluorescent signal immediately 
after IM injection (0 Hours). However, two hours after treatment a fluorescent signal was 
observed in the bladder area. We were unable to quantify the amount of peptide remaining 
in the ischemic limbs due to the interference caused by the fluorescent signal in the 
bladder area.  
 
 
Figure 8: Representative images of in vivo fluorescent imaging. BALB/c mice received IM 
treatment of VEGFmp or HoVEGFmp. At 0 and 2 hours after treatment, in vivo fluorescent 
imaging was done. Scale represents arbitrary fluorescent units. 
 
To determine the biodistribution of HoVEGFmp, a second set of BALB/c mice underwent 
femoral ligation followed by an IM injection of either VEGFmp or HoVEGFmp (55μL, 
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4.64µM, 1000ng, 0.255nmol total) 24 hours after surgery. Animals were then sacrificed at 
2, 6, and 18 hours after treatment, and the following organs were dissected and imaged 
using the Xenogen IVIS 100 imaging system: ischemic hindlimb, non-ischemic hindlimb, 
liver, lung, spleen, and kidney. The fluorescence levels of each organ were quantified, and 
the fold change in fluorescence (i.e.: ischemic hindlimb/non-ischemic hindlimb, liver/non-
ischemic hindlimb, etc.) was reported. As shown in Figure 9A, no differences were 
observed between the ischemic hindlimbs of animals treated with VEGFmp or HoVEGFmp 
at any time point. Two hours after treatment, large increases in fluorescent levels were 
observed (257.4 fold change for VEGFmp, 156.1 fold change for HoVEGFmp), but by 18 
hours after treatment, most of the fluorescent signal had been cleared (72.2 fold change 
for VEGFmp, 6.6 fold change for HoVEGFmp). Similarly, off target organs showed no 
differences between VEGFmp and HoVEGFmp treatments at any time points (Figure 9B-
E). The largest signals were observed in the kidneys (fold changes between 3.7 and 14.9), 





Figure 9: Quantification of ex vivo fluorescent signal. BALB/c mice received IM treatment 
of VEGFmp or HoVEGFmp. At 2, 6, and 18 hours after treatment, the organs of each 
mouse were dissected, ex vivo fluorescent imaging was done, and fluorescent signals 
were quantified. (A) Ischemic hindlimbs. (B) Liver. (C) Kidney. (D) Lung. (E) Spleen. (A-
E) Fold change to non-ischemic hindlimb, two-way ANOVA not significant. Bars represent 
Mean ± SEM, n=3-4. 
 
Immediately after ex vivo imaging, the tissue obtained from the ischemic hindlimbs was 
flash frozen and then homogenized. Immunoprecipitation was performed using a VEGFR-
2 antibody. Western blot analysis was performed using phospho-tyrosine (p-Tyr) kinase 
and VEGFR-2 antibodies to determine if either VEGFmp or HoVEGFmp treatment had 
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activated the VEGFR-2 signaling pathway. Figure 10A shows a representative image of 
the western blot membranes that were obtained. Figure 10B shows the quantification of 
the western blots. Even though higher levels of phosphorylation were observed at 18 
hours after treatment, no significant differences were observed between VEGFmp, 
HoVEGFmp, and PBS treated controls.  
 
 
Figure 10: Western blot analysis of hindlimb tissue samples. BALB/c mice received IM 
treatment of VEGFmp or HoVEGFmp. At 2, 6, and 18 hours after treatment, hindlimbs 
were dissected, homogenized, and immuneprecipitated with VEGFR-2 antibody. Western 
blot analysis was performed with p-Tyrosine Kinase and VEGFR-2 antibodies. (A) 
Representative image of Western blots. (B) Quantification of Western blots normalized to 
PBS treated controls (black line). (B) Two-way ANOVA not significant. Bars represent 





A new imaging system (In Vivo Xtreme, Bruker Corporation) was used for this and 
subsequent imaging studies. A dose of 1000ng of HoVEGF165 or VEGF165-Dy was used, 
as preliminary studies showed that this dose saturated the imager when placed on a 96 
well plate, and the dose was within the range of doses reported in other in vivo studies 
with mice (0.1 to 3µg) [37, 76]. 
 
BALB/c mice underwent femoral ligation followed by an IM injection of PBS, VEGF165-Dy, 
or HoVEGF165 (55μL, 0.87µM, 1000ng, 0.049nmol total) 24 hours after surgery. Animals 
were imaged in vivo before treatment and at 0, 2, 6, 24, 48 and 168 hours after treatment. 
Fluorescence levels of ischemic and non-ischemic hindlimbs were quantified, and fold 
change in fluorescence (ischemic hindlimb/non-ischemic hindlimb) was reported for each 
animal. Figure 11A shows representative images obtained with the new In Vivo Xtreme 
fluorescent imager. Figure 11B shows analysis of in vivo imaging data. VEGF165-Dy was 
significantly greater than PBS 2 hours (2.66 vs 1.03, p<0.01) and 6 hours (2.47 vs 1.05, 
p<0.01) after treatment. Similarly, HoVEGF165 was significantly greater than PBS 2 hours 
(2.13 v 1.03, p<0.05) and 6 hours (2.16 vs 1.05, p<0.05). No significant differences 





Figure 11: In vivo fluorescent imaging. BALB/c mice received IM treatment of PBS, 
VEGF165-Dy, or HoVEGF165. At 0, 2, 6, 24, 48 and 168 hours after treatment, in vivo 
fluorescent imaging was done, and fluorescent signals were quantified. (A) Representative 
in vivo fluorescent images. (B) Quantification of in vivo fluorescent signal in ischemic 
hindlimbs. (A) Scale represents arbitrary fluorescent units. (B) Fold change to non-
ischemic hindlimb, two-way ANOVA (p<0.05) with Bonferroni post hoc, *p<0.05, **p<0.01. 
Bars represent Mean ± SEM, n=3-6. 
 
BALB/c mice underwent femoral ligation followed by an IM injection of PBS, VEGF165-Dy, 
or HoVEGF165 (55μL, 0.87µM, 1000ng, 0.049nmol total) 24 hours after surgery. Animals 
were then sacrificed at 24, and 168 hours after treatment, and the following organs were 
dissected and imaged: ischemic hindlimb, non-ischemic hindlimb. Figure 12A shows 
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representative ex vivo images of hindlimbs 24 hours after treatment. Figure 12B shows 
quantification of these images. VEGF165-Dy was significantly different than PBS at 24 (2.59 
vs 1.02, p<0.05) and 168 (2.43 vs 1.08, p<0.01) hours after treatment. No significant 
differences between HoVEGF165 and VEGF165-Dy, or HoVEGF165 and PBS were observed 
at any time point. 
 
 
Figure 12: Ex vivo fluorescent imaging. BALB/c mice received IM treatment of PBS, 
VEGF165-Dy, or HoVEGF165. At 24 and 168 hours after treatment, the hindlimbs of each 
mouse were dissected, ex vivo fluorescent imaging was done, and fluorescent signals 
were quantified. (A) Representative ex vivo fluorescent images at 2 hours after treatment. 
(B) Quantification of ex vivo fluorescent signal in ischemic hindlimbs. (A) Scale represents 
arbitrary fluorescent units. (B) Fold change to non-ischemic hindlimb, two-way ANOVA 




3.2.5: Targeting of Hoechst Compounds in Animal Model of PAD 
To determine the effectiveness of our targeted delivery approach, the targeting of our 
compound was evaluated after an IV injection in a HLI model using BALB/c mice.  
 
3.2.5.1: HoVEGFmp 
For our treatment groups, we decided to deliver 1000ng of VEGFmp or HoVEGFmp in 
110µL of PBS IV. This treatment is the same as the one used for retention studies, with a 
molarity of 2.32µM and total of 0.255nmol being delivered. In pilot studies, as little as 10µL 
of compound at this concentration was visible using the In Vivo Xtreme fluorescent imager 
when injected directly to leg of mouse cadavers. 
 
BALB/c mice underwent femoral ligation followed by an IV injection of PBS, VEGFmp, or 
HoVEGFmp (110μL, 2.32µM, 1000ng, 0.255nmol total) 24 hours after surgery. Animals 
were imaged in vivo before treatment and at 0 and 24 hours after treatment. As shown in 
Figure 13A, no detectable levels of the compound were found in the ischemic legs at any 
time point after treatment (only 2 hour time point shown). At 2 hours after treatment, 
fluorescent signal was observed over the bladder of animals imaged. Fluorescent levels 
in vivo were not quantified due to the absence of signal. Animals were then sacrificed at 
either 2 or 24 hours after treatment, and the ischemic and non-ischemic hindlimbs were 
imaged. As shown in Figure 13A, a weak signal was observed in the ischemic hindlimbs 
compared to the contralateral non-ischemic hindlimb of animals treated with HoVEGFmp 
and VEGFmp (VEGFmp treated animal not shown). Quantification of this signal (Figure 
13B) showed the VEGFmp was significantly greater than HoVEGFmp (1.64 vs 1.33, 
p<0.01) and PBS (1.64 vs 1.16, p<0.05) at 2 hours after treatment. However, no significant 





Figure 13: In vivo and ex vivo fluorescent imaging. BALB/c mice received IV treatment of 
PBS, VEGFmp, or HoVEGFmp. At 2 hours after treatment, in vivo fluorescent imaging 
was done. At 2 and 24 hours after treatment, the hindlimbs of each animal were dissected, 
ex vivo fluorescent imaging was done, and fluorescent signals were quantified. (A) 
Representative in vivo and ex vivo fluorescent images. (B) Quantification of ex vivo 
fluorescent signal in ischemic hindlimbs. (A) Scale represents arbitrary fluorescent units. 
(B) Fold change to non-ischemic hindlimb, two-way ANOVA (p<0.05) with Bonferroni post 
hoc, *p<0.05, **p<0.01. Bars represent Mean ± SEM, n=7-9 for VEGFmp and HoVEGFmp 




Immediately after ex vivo imaging, the tissue obtained from the ischemic and non-ischemic 
hindlimbs was flash frozen and then homogenized. Two repeats of 200µL of homogenate 
were placed on each well of a black 96 well plate with a clear bottom for each sample. 
Each plate was imaged using the In Vivo Xtreme imager and the resulting images were 
quantified. Figure 14A shows a representative image of four different animals treated with 
HoVEGFmp and sacrificed 2 hours after treatment. Slightly stronger signal seems to be 
present in Ischemic hindlimbs (Isch) when compared to non-ischemic hindlimbs (N-Isch). 
Figure 14B shows the quantification of the fluorescent signal in these plates. No 




Figure 14: Ex vivo fluorescent imaging of homogenized hindlimbs. BALB/c mice received 
IV treatment of PBS, VEGFmp, or HoVEGFmp. At 2 and 24 hours after treatment, 
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hindlimbs were dissected, homogenized, and ex vivo fluorescent imaging was done on a 
black, clear bottom, 96 well plate. Fluorescent signals were then quantified. (A) 
Representative ex vivo fluorescent images. (B) Quantification of ex vivo fluorescent signal 
of homogenized hindlimbs. (A) Scale represents arbitrary fluorescent units. Isch: ischemic 
hindlimb, N-Isch: non-ischemic hindlimb. Numbers 3.1, 3.3, 4.1, and 4.3 represent four 
different animals treated with HoVEGFmp. (B) Fold change to non-ischemic hindlimb, two-
way ANOVA not significant. Bars represent Mean ± SEM, n=7-9 for VEGFmp and 
HoVEGFmp groups, n=1-2 for PBS groups. 
 
3.2.5.2: HoVEGF165 
During pilot studies, we were unable to detect any signal after IV treatment with 1000ng 
of either VEGF165-Dy or HoVEGF165 in vivo or ex vivo, as shown in Figure 15. Thus, we 
decided not to proceed with a targeting study for HoVEGF165 compound. 
 
 
Figure 15: Representative ex vivo fluorescent images. BALB/c mice received IV treatment 
of HoVEGFmp or HoVEGF165. At 2 hours after treatment, hindlimbs were dissected and 
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ex vivo fluorescent imaging was done. No signal was observed in animals treated with 




The delivery of VEGF recombinant protein for the treatment of PAD has been widely 
explored in pre-clinical and clinical studies [5, 7, 26, 27, 31, 36-39, 44, 67]. Despite 
promising results in different animal models, clinical studies have shown limited success 
[5, 7, 31, 44], probably due to the proteins short half-life, inadequate retention and 
targeting to target tissue, and numerous systemic side effects [5, 44]. To address these 
limitations, new techniques that provide localized, sustained delivery of protein to ischemic 
tissue have been developed [19, 26, 36, 37, 39, 40, 65, 77]. For example, VEGF has 
packed in injectable hydrogels [26, 27, 36, 38, 39], implantable hydrogels [37, 65], 
immunoliposomes [19], and nanoparticles [40]. However, the current processing 
conditions to make these hydrogels and nanoparticles can reduce the bioactivity of 
recombinant proteins such as VEGF [41], and although IM injection and surgical 
implantation are clinically feasible, the use of a non-invasive IV injection is preferred [19, 
21, 23, 26, 41-44]. Additionally, the use of VEGF mimetic peptides instead of full length 
VEGF has also been explored, since such peptides offer the same bioactivity and are 
easier to manipulate and package than full length VEGF [26, 65-67]. 
 
In this project we explored the use of a novel targeted delivery system using a modified 
Hoechst compound to deliver either VEGFmp or VEGF165 to necrotic tissue in an animal 
model of PAD. A similar modified Hoechst had previously been used in our lab to deliver 
IGF-1 to ischemic tissue in an animal model of myocarditis after an IV injection [23]. We 
hypothesized that these modified Hoechst compounds would bind to extracellular DNA 
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present in necrotic tissue, deliver VEGFmp or VEGF165 to the ischemic tissue, and 
promote angiogenesis and functional recovery. 
 
After the successful synthesis of our compounds (HoVEGFmp and HoVEGF165) we sought 
to verify that the bioactivity of our compounds was not compromised during the 
conjugation reactions. Using a permeability assay, we were able to evaluate if our 
compound would remain cell membrane impermeable and bind only to extracellular DNA. 
Similar to other modified Hoechst compounds used in our lab [21, 23], we confirmed that 
both of our compounds remained impermeable to the intact cell membranes of live cells, 
but both compounds were able to bind to DNA after these cell membranes were disrupted 
using methanol (Figure 2 and Figure 4). Using Western blot analysis and a tube formation 
assay, we were able to evaluate if our compound retained the angiogenic activity of VEGF. 
Western blot analysis showed slight increases in phosphorylation of ERK1/2 after 1 minute 
of treatment with VEGFmp (1.49 fold) or HoVEGFmp (1.69 fold) when compared to 
untreated controls, although these results were not significant (Figure 3). Western blot 
analysis has been previously used to evaluate the bioactivity of VEGF and VEGF mimetic 
peptides [26, 66, 76, 78], with the reported phosphorylation of VEGFR-2 being only 1.58 
fold higher than that of untreated controls [26]. Thus, increasing our sample size from n=2 
would allow us to accurately identify the slight changes in phosphorylation that are 
expected. The Tube formation assay showed extensive tube formation after treatment with 
HoVEGF165, VEGF165-Dy, VEGF165, and control (Figure 5). Although tube formation 
assays have been successfully to evaluate tube formation after angiogenic treatment [38, 
40, 76, 79], it is possible that either our treatment media or Geltrex contained growth 
factors that promote tube formation even in the absence of VEGF, as has been reported 
by others in our lab. Thus, better control of treatment factors would allow us to properly 
evaluate the angiogenic activity of our compound using a tube formation assay. In 
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summary, we were able to verify the bioactivity of the DNA binding component of our 
compound, but the evaluation of the bioactivity of the angiogenic component of our 
compound remains inconclusive. 
 
We proceeded to study the retention and targeting effects of our compounds in an in vivo 
model of HLI (Figure 6) [26, 27, 36-39, 67, 71-74, 80, 81]. Despite this model being 
extensively used, different levels of ischemia have been reported depending on the strain 
of mice used and the extent of femoral vessel damage [71, 72, 74, 80, 81]. We used 
BALB/c mice and a partial femoral ligation at two sites, near the origin of the deep femoral 
artery and near the origin of the saphenous artery, to induce moderate levels of ischemia. 
To evaluate the extent of necrosis, we measured the levels of DNA present in the serum 
of mice up to 48 hours after femoral ligation. We compared our results to a different model 
of ischemia (MI), since we had previously been successful in targeting necrosis in this 
model [23]. We observed increases in the blood levels of DNA by 24 hours after either HLI 
and MI surgical procedures (Figure 7), although these changes were not significantly 
different than control probably due to the low number of animals used for this study (n=2-
4). Although serum DNA levels do not necessarily correlate with the extent of necrosis, 
they indirectly suggest that necrosis is indeed present by 24 hours. 
 
We performed two sets of in vivo studies for each compound: (1) a retention study after 
IM injection of our compound, and (2) a targeting study after IV injection of our compound.  
 
For HoVEGFmp, retention studies demonstrated that our compound was not preferentially 
retained in ischemic tissue when compared to VEGFmp control (Figure 8, Figure 9). The 
presence of fluorescent signal in the bladder in in vivo images (Figure 8) and the large fold 
increases in fluorescence in the kidneys (3.7 to 14.9 fold) when compared to other off 
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target organs in ex vivo analysis (Figure 9C) suggests that the peptide was probably 
excreted through the renal system. Furthermore, treatment with either VEGFmp or 
HoVEGFmp did not lead to further activation of VEGFR-2 in ischemic hindlimbs in vivo 
(Figure 10). It is possible that this is due to the angiogenic activity of our compound being 
compromised after the addition of a fluorophore and/or the conjugation with Hoechst-
thiopyridyl. Targeting studies using HoVEGFmp, demonstrated that our compound did not 
preferentially target ischemic hindlimbs when compared to VEGFmp (Figure 13, Figure 
14). In vivo images demonstrated fluorescent signal in the bladder, similar to that observed 
in retention studies (Figure 13A). In contrast to retention studies, the fluorescent signal of 
HoVEGFmp treated animals in ex vivo analysis was not significantly different than that of 
PBS treated control animals (Figure 13B). One possible reason for this is that perhaps our 
compound was only present in low quantities deep in the muscle tissue. In order to extract 
our compound from the muscle tissue, we homogenized the tissue and measured the 
fluorescent signal of the resulting homogenate (Figure 14); however, no differences 
between HoVEGFmp, VEGFmp or PBS treated animals were observed. In summary, our 
HoVEGFmp compound did not show improvements in retention or targeting when 
compared to controls. 
 
For HoVEGF165, retention studies demonstrated that our compound was not preferentially 
retained in ischemic tissue when compared to VEGF165-Dy control (Figure 11, Figure 12). 
Interestingly, in vivo fluorescent imaging showed no signal over the bladder of any of the 
animals imaged (Figure 11A). The fold change in fluorescence observed in ex vivo studies 
(Figure 12B) was lower than that observed in retention studies with HoVEGFmp (Figure 
9). This could be due to differences in dosing (HoVEGFmp: 1000ng=0.255nmol; 
HoVEGF165: 1000ng=0.049nmol of compound) or imaging system used. Targeting studies 
for HoVEGF165 were not performed, as a pilot study showed that no signal was observed 
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after IV injection of the compound (Figure 15). In summary, our HoVEGF165 did not show 
improvements in retention or targeting when compared to controls. 
 
One possible explanation for the lack of retention and targeting of our compounds is the 
rapid breakdown of our compounds at the site of injury or in blood plasma. Blood plasma 
contains a number of different proteinases (serine-, cysteine-, aspartic-, and metallo-) 
whose activity is usually kept in check by proteinase inhibitors (α1 antitrypsin, α2 
antiplasmin and α2 macroglobulin) [82-84]. In sites inflammation, the presence of 
macrophages and neutrophils leads to an increase in the amount of proteinases and 
results in the rapid breakdown of circulating proteins and peptides [82, 83]. Interestingly, 
the breakdown of peptides has been observed to be much faster than that of proteins even 
in the absence of inflammation, with many peptides having a half-life in the order of 
seconds in human plasma [82, 83].  
 
In our retention experiments, it is possible that an inflammatory response to the femoral 
ligation surgery increased the levels of proteinases present, particularly at the injury site. 
This, in turn, lead to the rapid breakdown of both peptides (HoVEGFmp) and proteins 
(HoVEGF165) delivered to the injury site for retention studies. Since peptides tend to be 
hydrolyzed much faster than proteins, we would expect to see our HoVEGFmp compound 
being cleared from the injury site much faster than HoVEGF165. Unfortunately, an accurate 
comparison between our two compounds was not possible due to the use of different 
doses, fluorescent imaging systems, and end points. In our targeting experiments, it is 
possible that both of our compounds were broken down by proteinases before reaching 
our target tissue. To circumvent these limitations, both peptide and protein based 
compounds could be modified. For example, glycosylation, PEGylation, substitution of 
peptide cleavage sites, modification to secondary peptides structures, or binding to carrier 
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proteins such albumin has been proposed [82-85]. In our lab, conjugation to streptavidin 
(~50kDa) improved the half-life of IGF-1 after IV delivery [23]. 
 
A second possible explanation for the lack of retention and targeting of our compounds is 
the rapid breakdown and excretion of our compound through the kidneys. It is known that 
filtration of peptides and proteins through the kidneys depends on their size, shape and 
charge [82-84, 86, 87]. Peptides (<5kDa) usually pass into the ultrafiltrate unimpaired, with 
a peptide clearance/inulin clearance of almost 1 (range is from 0 for albumin to 1 for small 
peptides) [82, 84, 86]. Peptides can then be excreted unchanged or they can be 
hydrolyzed by brush border membrane proteinases, with the resulting peptide fragments 
and amino acids being reabsorbed [82, 84, 86]. For proteins of ~20kDa size, clearance 
ranges from 0.5 to 0.8 depending on their charge [82]. Here, proteins are collected in 
endocytic vacuoles that fuse with lysosomes, breakdown proteins, and return amino acids 
into circulation [82, 84, 86].  
 
In our retention and targeting experiments, we were able to observe the presence 
HoVEGFmp but not HoVEGF165 in the anatomical areas that correspond to the bladder 
(Figure 8, Figure 11A, Figure 13A). This suggests that our HoVEGFmp was being broken 
down in the brush border membrane of the kidneys, with the resulting amino acids being 
reabsorbed while the fluorophore was excreted through the renal system. HoVEGF165, on 
the other hand was internalized into endocytic vacuoles, where the fluorophore was 
probably broken down instead of being secreted through the renal system. In either case, 
modification of both peptide and protein based compounds would be necessary to 




Finally, for in vivo studies we used an animal model of HLI with BALB/c mice. BALB/c mice 
have been reported to have fewer or narrower collaterals when compared to C57BL/6 
mice, and we would expect to see more severe ischemia and necrosis in BALB/c mice 
[71]. Even though this provides more extracellular DNA for our compounds to target, the 
lack of collaterals could limit the amount of compound that can be delivered to areas of 
ischemia and necrosis. 
 
Our studies have explored a novel targeting technique for the treatment of PAD. Although 
our results were not what we expected, the insights obtained here can be used to advance 
the development of new techniques for the treatment of PAD.   
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Cardiomyopathy and myocarditis are an increasing global medical problem [52]. The 
prevalence of myocarditis is estimated to be about 22 per 100,000 patients, with the global 
number of deaths attributed to cardiomyopathy and myocarditis increasing by 40.8% 
between 1990 and 2010 (from 286,800 to 403,900) [1, 53]. Furthermore, these diseases 
are also associated with great morbidity. For example, myocarditis accounts for ~11% of 
heart failure cases and it is the most common cause for heart transplantation worldwide 
due to the lack of appropriate diagnostics and treatments [54]. In pediatric populations in 
the United States, the incidence of cardiomyopathy in infants less than 1 year of age is 
estimated to be 8.34 cases per 100,000 [1]. The most common form of cardiomyopathy in 
children is dilated cardiomyopathy (DCM), with an estimated annual incidence in infants 
less than 1 year of age of 4.40 cases per 100,000 [1]. Although the cause of DCM remains 
unidentified in 66% of cases, myocarditis accounts for 46% of the known causes [1, 52]. 
 
Myocarditis refers to localized or diffuse inflammation of the myocardium [9-11]. It is a 
complex disease that can be caused by infections (bacterial, rickettsial, mycotic, 
protozoan, and viral agents), cardiotoxic agents (drugs, toxins, and alcohol), or 
autoimmune disease, but many cases remain idiopathic [9, 11, 12, 54-59]. Although the 
exact mechanisms through which myocarditis develops are not well understood, evidence 
suggests that both the innate and adaptive immune systems of the host are involved [10, 
12, 53, 54]. For example, in animal models of viral myocarditis due to Coxsackie B3 Virus, 
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three different phases can be observed [11, 12, 53, 54, 56]. In the first phase (first few 
days), the virus infects cardiomyocytes, replicates, and induces the destruction of 
cardiomyocytes [11, 56-58]. The innate immune system is activated through different 
pathways (pro-inflammatory cytokines, suppressors of cytokine signaling proteins, toll-like 
receptors), and an invasion of natural killer cells and macrophages followed by T 
lymphocytes is observed [11, 12, 53, 54, 57, 58]. In the second phase (weeks to months), 
the presence of the viral genome leads to immune dysregulation, activation of the adaptive 
immune system through viral specific T-cells, the presence of inflammatory cellular 
infiltration, autoimmune reactions, and continuous injury to cardiomyocytes [11, 12, 56-
58]. In the third phase, the presence of circulating cross reacting autoantibodies in addition 
to the virus-induced cardiomyocyte injury leads to remodeling of the heart and the 
development of DCM [11, 12, 53, 56-58]. 
 
The clinical presentation of patients with myocarditis tends to be heterogeneous. However, 
based on the different clusters of symptoms observed, it can be classified into different 
presentation types: acute coronary syndrome like, new-onset heart failure, life threatening 
arrhythmias, and chronic heart failure [9, 12, 55]. However, patients often present with 
nonspecific symptoms or without any symptoms at all, and infants in particular are often 
unable to verbalize what these symptoms are [12, 56, 59]. 
 
4.1.2: Current Diagnosis of Myocarditis 
The heterogeneous etiology, pathophysiology, and clinical presentation of myocarditis 
makes it one of the most challenging diagnosis in cardiology and leads to the under-
diagnosis of cases of myocarditis [9, 12]. The gold standard for the diagnosis of 
myocarditis is endomyocardial biopsy (EMB) complemented by immunohistochemistry 
and PCR [9, 11, 12, 53, 55-57, 60]. This procedure is considered to be safe when 
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performed by experienced physicians; however, it is an invasive procedure that has some 
risk of serious complications, particularly in children with rates as high as 10.6% [9, 12, 
57, 59, 61]. These complications include cardiac perforation with tamponade, ventricular 
or supraventricular arrhythmias, heart block, pneumothorax, hemothorax, puncture of 
central arteries, pulmonary embolization, venous hematoma, damage to the tricuspid 
valve, stroke, and death [9, 12, 55, 57, 61]. Furthermore, studies that compared the 
performance of EMB to the ex vivo evaluation of hearts with myocarditis found that EMB 
misses approximately half of the diagnoses, even when 10 biopsy samples were analyzed 
[9]. Due to the diffuse nature of myocarditis, it is estimated that 17 biopsies are needed to 
reach a sensitivity of only 80% [9, 57], and thus there is a decreased reliance on EMB 
particularly in pediatric populations in the United States [56, 57]. Due to these limitations, 
other noninvasive diagnostic modalities have been explored. For example, cardiac 
magnetic resonance (CMR) can be used to demonstrate typical features of acute 
myocarditis such as dysfunction, edema and necrosis [9, 53, 56, 57, 59, 60]. Studies that 
compared the performance of CMR to biopsy samples reported sensitivities between 47% 
and 74% depending on the modality used [9]. Despite improvements in the diagnostic 
criteria used with CMR, the diagnosis of a substantial number of patients may still be 
missed, particularly in patients in the chronic phase of myocarditis [9, 60]. Furthermore, 
CMR cannot be used to determine the underlying cause of myocarditis, to stratify the risk 
of different patients, and the findings have not yet been validated in pediatric patients [9, 
56, 57]. Other noninvasive diagnostic modalities, such as electrocardiogram, chest 
radiography, or echocardiography have low diagnostic value, sensitivity, and specificity 




4.1.3: Targeted Molecular Imaging 
Modifications to noninvasive imaging techniques that allow for the targeted molecular 
imaging of myocarditis are currently being explored. For example, targeted molecular 
imaging using fluorine-19 in CMR has been shown to detect myocardial inflammation in 
an animal model of experimental autoimmune myocarditis (EAM) through the 
incorporation of fluorine-19 into macrophages, dendritic cells, and granulocytes [62]. 
However, fluoride-19 is not specific to myocarditis and can be incorporated by 
macrophages and monocytes in other disease processes such as pneumonia, allograft 
rejection, cardiac ischemia, and cerebral ischemia [62]. Similarly, microbubbles with 
modifications or coated with antibodies targeting leukocytes, endothelial cells, and T-
lymphocytes were shown to enhance ultrasound signal in animals with EAM; however, the 
use of antibodies in therapies is limited by production costs, low tissue penetration, and 
host immune response to antibody [63, 64]. Thus there is still a need for improved 
technologies for the appropriate diagnosis and timely treatment of myocarditis. 
 
4.1.4: Approach 
Using an in vivo phage display library [88-92], we identified potential peptides that can be 
used for molecular imaging or targeted drug delivery in patients with myocarditis. We 
hypothesized that these peptides can be used to target hearts with myocarditis after 
intravenous (IV) delivery (Figure 16). These peptides would address the limitations of 
previous targeted molecular imaging studies and would provide another tool to improve 





Figure 16: Schematic of targeting peptides for the diagnosis of myocarditis. Biotinylated 
targeting peptides binding to fluorescent streptavidin can be used for the diagnosis of 
myocarditis in vivo. 
 
4.2: Methods and Results 
 
4.2.1: Animal Model of Experimental Autoimmune Myocarditis 
We used an animal model of EAM in which male BALB/c mice (6-8 weeks old) were 
immunized at 0 and 7 days with subcutaneous injections containing 150µg of myosin 
heavy-chain α peptide (MyH: Ac-SLKLMATLFSTYASAD-OH, New England Peptide) 
dissolved in 100µL of PBS and emulsified with 100µL of complete Freund’s adjuvant (CFA, 
Sigma) [62, 64, 93-99]. For control groups, animals were either immunized at 0 and 7 days 
with subcutaneous injections containing 100µL of PBS emulsified with 100µL of CFA, or 
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were not treated at all. In this animal model, it is expected that animals immunized with 
MyH/CFA will develop inflammatory infiltrates in their hearts at 10 days after initial 
immunization, and that these infiltrates will peak around 21 days and will be cleared by 56 
days after initial immunization [55, 99]. However, only 40-60% of animals develop 
myocarditis, and these animals usually have variable disease severity as determined by 
the degree of infiltration observed on H&E stained sections [62, 64, 93-99]. 
 
4.2.2: Baseline Characteristics 
A total of 94 animals that were used in our ex vivo peptide screening (n=31) and in vivo 
peptide screening (n=63) experiments were euthanized at 21 days after initial 
immunization and histologically scored for disease severity using H&E staining. These 
animals were assigned to one of the following treatment groups: untreated controls (n=14), 
immunized with PBS/CFA (n=16), and immunized with MyH/CFA (n=64). Scoring for 
disease severity was based on the amount of infiltration present. The protocols that have 
been used to score animals for myocarditis and myocarditis severity vary among different 
studies and are subject to inter- and intra-observer variability [62, 64, 93-99]. To account 
for this, we decided to use a well-defined protocol that is similar to ones that have been 
more recently published [62, 64]. Briefly, the left ventricle (LV) was divided into four 
quadrants. Each quadrant and the right ventricle (RV) were then scored on a scale of 0 to 
4, with 0 representing no inflammatory infiltrates, 1 representing small foci of leukocytes 
between cells, 2 representing larger foci of > 100 leukocytes, 3 representing >10% of the 
quadrant cross section involved with inflammatory infiltrates, and 4 representing >30% of 
the quadrant cross section involved with inflammatory infiltrates. The sum of the scores 
for each LV quadrant and the RV (H&E Sum Score) was then used to classify the severity 
of myocarditis as follows: no myocarditis: H&E Sum Score ≤ 3; mild myocarditis: 4 ≤ H&E 
Sum Score ≤ 7; and severe myocarditis: H&E Sum Score ≥ 8. To prevent any bias, all 
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scoring was conducted and analyzed by investigators blinded to the animal’s treatment 
group. In line with expectations, a total of 42 animals immunized with MyH/CFA (65.63%) 
developed myocarditis, with 28 animals being scored as mild myocarditis (43.75%) and 
14 animals being scored as severe myocarditis (21.88%). None of the animals immunized 
with PBS/CFA or left untreated developed myocarditis, and in subsequent analyses these 
animals were grouped together as the Control group (n=30). Representative images of 
animals immunized with MyH/CFA with no myocarditis, mild myocarditis, and severe 
myocarditis are shown in Figure 17. Additionally, no differences in any functional 
parameters measured by echocardiography or body weight were observed between 
groups (Figure 18 and Figure 19), suggesting that the inflammatory infiltrates are present 





Figure 17: Representative H&E images of animals with and without myocarditis. Heart 
sections of animals immunized with MyH/CFA were stained with H&E, imaged, scored, 
and classified as no myocarditis, mild myocarditis, and severe myocarditis. Black 
arrowheads represent the approximate location of the areas that were amplified. 






Figure 18: Echocardiography data of animals 21 days after initial immunization. Animals 
assigned to ex vivo and in vivo peptide screening experiments underwent 
echocardiography analysis 21 days after initial immunization. Data for different parameters 
measured is presented. Median values (horizontal line), 25% to 75% percentiles (box), 
and range of values (whiskers). Control, n=22; No Myocarditis: n=18; Mild Myocarditis: 





Figure 19: Body weight of animals through 21 days after initial immunization. The body 
weight for animals assigned to ex vivo and in vivo experiments was measured at 0, 7, and 
21 days after initial immunization. Median values (horizontal line), 25% to 75% percentiles 
(box), and range of values (whiskers).Two-way ANOVA (p<0.05) showed an effect of time 
but not treatment group. 
 
4.2.3: In Vivo Phage Display 
We used in vivo phage display to identify potential targeting peptides for the diagnosis of 
myocarditis. The experimental setup for our in vivo phage display experiments is shown 
in Figure 20. We performed a total of 3 cycles or pannings, similar to other published in 
vivo phage display experiments [88-91]. Briefly, at 21 days after initial immunization 
animals received an IV injection through the tail vein with either a linear 12 amino acid 
(AA) peptide phage library (Ph.D. 12 Phage Display Peptide Library Kit, New England 
BioLabs, #E8110S) or an empty control phage (M13KE, New England BioLabs, 
#EN0316S) at a concentration of 1x109 plaque-forming units (pfu)/µL, as suggested by 
the manufacturer. For each panning, animals were divided into the following treatment 
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groups: MyH PhD: immunized with MyH/CFA and injected with the phage library (n=5 per 
panning); MyH Cont: immunized with MyH/CFA and injected with the control phage (n=4-
5 per panning); PBS PhD: immunized with PBS/CFA and injected with the phage library 
(n=2-3 per panning); and PBS Cont: immunized with PBS/CFA and injected with the 
control phage (n=2 per panning). The phages were allowed to circulate for 10 minutes 
after being injected, at which point animals were euthanized and the hearts were excised, 
washed extensively in PBS and flash frozen. Since only 40-60% of animals were expected 
to develop myocarditis, the hearts for each of the four treatment groups were pooled 
together, and the phages were recovered through tissue homogenization and amplified in 
bacteria. The phages isolated in panning 1 were then reinjected to animals in the same 
treatment group in panning 2, and the phages isolated in panning 2 were reinjected to 
animals in the same treatment group in panning 3. 
 
 
Figure 20: Flow diagram of in vivo phage display experiments. Animals underwent three 
different rounds or pannings of in vivo phage display. The phages isolated in panning 1 
were reinjected to animals in the same treatment group in panning 2, and the phages 
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isolated in panning 2 were reinjected to animals in the same treatment group in the final 
panning 3. 
 
Although we expected to see preferential accumulation in the number of phages binding 
to the hearts of animals in the MyH PhD group in each subsequent panning when 
compared to the other treatment groups, this was not observed (Table 1). This is probably 
due the variability present in the tittering process and the single data point present for 
each panning after pooling animals in the same treatment group together.  
 








MyH PhD 3.03E+11 9.40E+10 3.60E+05 
MyH Cont. 3.86E+11 1.12E+11 2.15E+05 
PBS PhD 3.12E+11 1.93E+11 6.50E+04 
PBS Cont. 1.78E+11 9.10E+10 4.13E+05 
 
After the third panning, a total of 110 colonies for MyH PhD, 16 colonies for MyH Cont, 
110 colonies for PBS PhD, and 16 colonies for PBS Cont were selected for DNA 
sequencing. Each colony was amplified using PCR with custom designed primers (sense: 
CACCGTTCATCTGTCCTCTTTC, antisense: TCACCGTACTCAGGAGGTTTAG). After 
cleaning up the PCR products, the amplicons were sent for sequencing. It is possible that 
screening more colonies could have yielded other promising targets, but such screening 
would have been both time and resource intensive. As expected, none of the colonies 
isolated from MyH Cont and PBS Cont treatment groups showed the presence of a 12 AA 
linear peptide sequence. For MyH PhD, a total of 46 colonies sequenced contained a 12 
AA linear peptide sequence with a total of 36 unique sequences being identified. For PBS 
PhD, a total of 41 colonies sequenced contained a 12 AA linear peptide sequence with a 
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total of 37 unique sequences identified. Although screening of all peptides identified in the 
MyH PhD group would have been ideal, we selected six different peptides for further ex 
vivo and in vivo screening (Table 2). Peptides MyH-PhD-09 and MyH-PhD-120 were 
selected because each sequence was repeated 5 times, suggesting that it had a higher 
affinity for animals with myocarditis. Peptides MyH-PhD-04, MyH-PhD-05, MyH-PhD-13, 
and MyH-PhD-16 were selected after BLAST and literature review of each peptide 
sequence, as each had homology with a component of different cell types potentially 
involved in the immune response (astrocytes, T lymphocyte, endothelial cells, etc.). It is 
possible that some of the other peptides that were not selected for ex vivo and in vivo 
screening could have been good candidates for targeting myocarditis, though screening 
so many candidates is resource intensive. It is important to note that none of the peptides 
selected were also found in the peptides identified in the PBS PhD treatment group, 
suggesting that the selected peptides target cardiac tissue with myocarditis and not just 
healthy cardiac tissue. For ex vivo and in vivo screening experiments, custom biotinylated 
peptides of each sequence were used (New England Peptide). 
 
Table 2: Sequences and known homology for the selected potential targeting peptides. 
Peptide Name Peptide Sequence Frequency Known Homologies 
MyH-PhD-04 LGDLHNRDNNSA 1 pericentriolar material 1 protein; protocadherin; plexin C1 
MyH-PhD-05 HSRTDYVQASYP 1 
pancreatic lipase-related protein 2; 
cytotoxic T lymphocyte lipase; Duox 2 
protein 
MyH-PhD-09 GLHTSATNLYLH 5 pannexin-3; olfactory receptor 460; cubilin precursor 
MyH-PhD-13 GDGNSVLKPGNW 1 
trans-2-enoyl-CoA reductase, 
mitochondrial precursor; Dhm1 
protein; Xrn protein 
MyH-PhD-16 TASDVPRSRPHS 1 
cell division cycle associated 7; plexin 
D1; Cell adhesion molecule 4 
precursor 
MyH-PhD-120 SGVYKVAYDWQH 5 helicase, mus308-like; lipase, member 01 precursor; Gm8978 
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4.2.4: Ex Vivo Peptide Screening 
To assess the targeting potential of each selected peptide ex vivo, different frozen heart 
sections of 31 animals at 21 days after being either untreated (n=6), immunized with 
PBS/CFA (n=9), or immunized with MyH/CFA (n=16) were stained with H&E and each of 
the six biotinylated peptides (Table 2). Each animal was assessed for disease severity as 
previously described. A total of 13 out of 16 animals immunized with MyH/CFA (81.25%) 
developed myocarditis (mild: n=8; severe: n=5), while none of the animals that were either 
not treated or immunized with PBS/CFA developed myocarditis (control, n=15). Similar to 
disease severity scoring, each animal was also scored for the binding of each of the six 
targeting peptides. Briefly, the LV was divided into four quadrants. Each quadrant and the 
RV were then scored on a scale of 0 to 3, with 0 representing no stained cells, 1 
representing few scattered stained cells, 2 representing the presence of a few stained foci, 
and 3 representing the continuous presence of stained tissue. The sum of the scores for 
each LV quadrant and the RV (Sum Score of peptide) was used to assess the degree of 
staining of each peptide, with a Sum Score of peptide > 2 being considered as positive 
staining. To prevent any bias, all scoring was conducted and analyzed by investigators 
blinded to the animal’s treatment group and the peptide being screened.  
 
For peptides MyH-PhD-04, MyH-PhD-09, MyH-PhD-13, and MyH-PhD-16, no positive 
staining was observed on any of the frozen sections of animals for any treatment group 
(control, no myocarditis, mild myocarditis, and severe myocarditis). These peptides were 
eliminated from consideration for future experiments. For peptide MyH-PhD-05, 0 out of 
15 animals in the control group (untreated or immunized with PBS/CFA), 1 out of 3 animals 
in the no myocarditis group, 8 out of 8 animals in the mild myocarditis group, and 4 out of 
5 animals in the severe myocarditis group had positive staining. Representative images 
show that MyH-PhD-05 staining corresponded to areas of increased leukocyte infiltration 
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(Figure 21), while the quantification of the Sum Score of MyH-PhD-05 shows a gradual 
increase in the amount of staining present as animals develop mild and severe myocarditis 
(Figure 22).  
 
 
Figure 21: Representative images of hearts stained with H&E and MyH-PhD-05. Black 
arrowheads on the whole heart H&E images represent the approximate location of the 
areas that were amplified in subsequent H&E images. MyH-PhD-05 staining corresponds 
to areas of increased leukocyte infiltration in animals with myocarditis. Fluorescent 






Figure 22: Quantification of ex vivo MyH-PhD-05 staining at 21 days. Median values 
(horizontal line), 25% to 75% percentiles (box), and range of values (whiskers). Control: 
n=15; No Myocarditis: n=3; Mild Myocarditis: n=8; Severe Myocarditis: n=5. One way 
ANOVA (p<0.05) with Tukey multiple comparison test, ***p<0.001, *p<0.05. 
 
For peptide MyH-PhD-120, 0 out of 15 animals in the control group, 1 out of 3 animals in 
the no myocarditis group, 3 out of 8 animals in the mild myocarditis group, and 4 out of 5 
animals in the severe myocarditis group had positive staining. Similar to MyH-PhD-05, 
MyH-PhD-120 staining corresponded to areas of leukocyte infiltration (Figure 23); 
however, quantification of Sum Score of MyH-PhD-120 showed a much weaker increase 
in staining as animals developed mild and severe myocarditis when compared to MyH-





Figure 23: Representative images of hearts stained with H&E and MyH-PhD-120. Black 
arrowheads on the whole heart H&E images represent the approximate location of the 
areas that were amplified in subsequent H&E images. MyH-PhD-120 corresponds to 
areas of increased leukocyte infiltration in animals with myocarditis. Fluorescent imaging: 





Figure 24: Quantification of ex vivo MyH-PhD-120 staining at 21 days. Median values 
(horizontal line), 25% to 75% percentiles (box), and range of values (whiskers). Control: 
n=15; No Myocarditis: n=3; Mild Myocarditis: n=8; Severe Myocarditis: n=5. One way 
ANOVA (p<0.05) with Tukey multiple comparison test, *p<0.05. 
 
To verify that this increased staining was specific to the heart, off target tissue (lung, liver, 
spleen, kidney, thigh) in three animals with severe myocarditis were stained with MyH-
PhD-05 or MyH-PhD-120. No off target binding of either MyH-PhD-05 or MyH-PhD-120 
was observed (Figure 25). For future experiments, we decided to focus on exploring the 





Figure 25: Representative images of organs stained with targeting peptides. The heart, 
lung, liver, spleen, kidney and thigh of animals with myocarditis were stained with MyH-
PhD-05 or MyH-PhD-120. Both MyH-PhD-05 and MyH-PhD-120 only stained the heart in 
animals with severe myocarditis. Fluorescent Imaging: 20x, Blue: DAPI (nuclei), Green: 




4.2.5: Peptide Screening in Animal Model of Myocardial Infarction 
To ensure that MyH-PhD-05 was targeting inflammation specific to myocarditis, we 
explored the ex vivo targeting potential of MyH-PhD-05 in animal model of myocardial 
infarction (MI). Briefly, adult male C57BL/6 mice (>8 weeks old, n=2) were subjected to 
permanent ligation of the left anterior descending coronary artery to induce MI [100, 101]. 
In this model, extensive infiltration of inflammatory cells is expected around 72 hours after 
MI induction [101]. After allowing the animals to recover for 3 days, the animals were 
euthanized and the hearts were dissected and processed into frozen sections. These 
frozen sections were then stained with MyH-PhD-05 and imaged. As shown in Figure 26, 
no staining of MyH-PhD-05 was observed in the peri-infarct or the non-infarct area of the 
hearts of animals with MI, suggesting that MyH-PhD-05 only targets inflammation in 
myocarditis and not MI. 
 
 
Figure 26: Representative images of hearts with MI stained with MyH-PhD-05. The non-
infarct area and the peri-infarct area of two animals with myocarditis were stained with 
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MyH-PhD-05. No staining of MyH-PhD-05 was observed. Fluorescent Imaging: Blue: 
DAPI (nuclei), Green: FITC (auto fluorescence), and Red: Cy5 (peptide). 
 
4.2.6: In Vivo Peptide Screening 
To assess the in vivo targeting potential of MyH-PhD-05 and MyH-PhD-120, each 
biotinylated peptide was conjugated with Streptavidin DyLight 650 (Thermo Fisher 
Scientific). At 21 days after the induction of EAM, each animal received a tail vein IV 
injection containing 1100ng of one of resulting compounds, S-MyH-PhD-05 or S-MyH-
PhD-120. The compound was allowed to circulate for 15 minutes after being injected, at 
which point animals were euthanized and the heart, lungs, liver, spleen, kidney, and thigh 
were dissected and immediately imaged using the In Vivo Xtreme Imaging System 
(Bruker). The spleen showed the lowest and least variable fluorescent signal across 
animals in all treatment groups, and the fold change in fluorescent signal relative to the 
spleen was reported for each organ of interest. A total of 63 animals were used for in vivo 
peptide screening in the following treatment groups: untreated controls (n=8), immunized 
with PBS/CFA (n=7), and immunized with MyH/CFA (n=48). A total of 29 out of 48 animals 
immunized with MyH/CFA (60.42%) developed myocarditis (mild: n=20; severe: n=9). 
Since we expected only 40-60% of animals immunized with MyH/CFA to develop 
myocarditis [62, 64, 93-99], we increased the number of animals being screened with our 
most promising compound S-MyH-PhD-05 (n=36) when compared with compound S-
MyH-PhD-120 (n=12). For animals treated with an IV injection of S-MyH-PhD-05 (n=43), 
the fluorescent signal in the hearts of animals with severe myocarditis (2.05±0.22, n=7) 
was significantly elevated compared to the hearts of animals in the control group 
(1.38±0.08, p<0.01, n=7), animals with no myocarditis (1.42±0.06, p<0.001, n=13), and 
with animals with mild myocarditis (1.52±0.05, p<0.01, n=16) as shown in Figure 27 and 
Figure 28. To determine if this trend was specific to a particular section of the heart, each 
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heart was excised into three different sections (the base, the midsection, and the apex) 
and imaged. The fluorescent signal in each of the three different sections followed a similar 
pattern to that observed in the whole heart. To determine if S-MyH-PhD-05 was also 
targeting other organs, the fluorescent signal in the lung, thigh, liver, and kidney were 
quantified. No significant differences between treatment groups were observed in any of 
these organs (Figure 29).  
 
 
Figure 27: Representative fluorescent images of hearts treated with S-MyH-PhD-05. The 
hearts of animals with and without myocarditis treated with IV S-MyH-PhD-05 were 
dissected and fluorescently imaged at 21 days after initial immunization. The whole heart 
(top panels) and three different sections (bottom panels) of one control animal and two 





Figure 28: Quantification of S-MyH-PhD-05 signal in hearts at 21 days. The ex vivo 
fluorescent signal in the hearts of animals treated with an IV injection of S-MyH-PhD-05 
at 21 days after initial immunization was quantified for the whole heart and for three 
different sections of the heart: the base, the midsection, and the apex. Fold change relative 
to spleen. Median values (horizontal line), 25% to 75% percentiles (box), and range of 
values (whiskers). Control: n=7; No Myocarditis: n=13; Mild Myocarditis: n=16; Severe 
Myocarditis: n=7. One-way ANOVA (p<0.05) with Tukey’s multiple comparison test, 





Figure 29: Quantification of S-MyH-PhD-05 signal in organs at 21 days. The ex vivo 
fluorescent signal in the lung, thigh, liver, and kidney of animals treated with an IV injection 
of S-MyH-PhD-05 at 21 days after initial immunization was quantified. Fold change relative 
to spleen. Median values (horizontal line), 25% to 75% percentiles (box), and range of 
values (whiskers). Control: n=7; No Myocarditis: n=13; Mild Myocarditis: n=16; Severe 
Myocarditis: n=7. One-way ANOVA (p<0.05) not significant for any organ. 
 
For animals treated with an IV injection of S-MyH-PhD-120 (n=20), the fluorescent signal 
in the hearts of animals with either mild (n=4) or severe myocarditis (n=2) were elevated 
compared to animals with no myocarditis (n=6) or in the control group (n=8) as shown in 
Figure 30. Nevertheless, a reduced number of animals were used to screen compound S-
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MyH-PhD-120, resulting in inconsistent in vivo targeting results. It is possible that with an 
increased number of animals a relationship similar to that observed for S-MyH-PhD-05 
would emerge for animals treated with S-MyH-PhD-120.  
 
 
Figure 30: Quantification of S-MyH-PhD-120 signal in hearts at 21 days. The ex vivo 
fluorescent signal in the hearts of animals treated with an IV injection of S-MyH-PhD-120 
at 21 days after initial immunization was quantified for the whole heart and for three 
different sections of the heart: the base, the midsection, and the apex. Fold change relative 
to spleen. Median values (horizontal line), 25% to 75% percentiles (box), and range of 
values (whiskers). Control: n=8; No Myocarditis: n=6; Mild Myocarditis: n=4; Severe 
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Myocarditis: n=2. One-way ANOVA (p<0.05) with Tukey’s multiple comparison test, 
*p<0.05, **p<0.01. 
 
It is important to reiterate that no differences in any functional parameters measured by 
echocardiography were observed at 21 days after initial immunization (Figure 18), 
demonstrating that detection of myocarditis by MyH-PhD-05 (and to a lesser extent MyH-
PhD-120) is possible in the absence of functional changes. Finally, due to the nature of 
the study and shortcomings in fluorescent imaging, we were not able to perform 
longitudinal, long-term studies to determine predictive value, though that will be an 
important next step in future studies. 
 
4.2.7: Immunohistochemistry 
We then used immunohistochemistry to identify the cell types in inflammatory infiltrates of 
myocarditis and their colocalization with MyH-PhD-05. Previous studies have shown that 
inflammatory infiltrates in myocarditis are predominantly CD4+ T-cells; however, 
monocytes, macrophages, dendritic cells, and granulocytes have also been identified [62, 
64]. We decided to investigate three different cell types in the inflammatory infiltrate using 
frozen sections of the hearts of mice with severe myocarditis (n=4). For each animal, 
different sections were stained with MyH-PhD-05 and either CD4 (T-cells), CD68 
(macrophages), or CD11b (monocytes). Fluorescent images were acquired, and the 
relative fluorescence from CD4, CD68, and CD11b staining along with their colocalization 
with MyH-PhD-05 was measured using Fiji software. As shown in Figure 31A, the different 
immune markers and MyH-PhD-05 only bound to regions with inflammatory infiltrates. 
These infiltrates were predominantly CD4+ T cells, and MyH-PhD-05 preferentially 
colocalized with CD4+ T cells and monocytes (Figure 31B and Figure 31C). However, the 
low resolution of fluorescent microscopy (several hundred nanometers) makes it difficult 
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to determine if the peptide is binding to intracellular components, cell surface components 
or extracellular components. We decided to use proteomic analysis to identify the potential 
binding partners of MyH-PhD-05, although future work can focus on using other 
techniques such as single cell flow cytometry and multiphoton imaging. 
 
 
Figure 31: Representative images and quantification of immune cells in myocarditis. A. 
Representative images of 3 different sections of the same animal with severe myocarditis 
stained with CD4 (T-cells), CD68 (Macrophages), and CD11b (Monocytes) and imaged at 
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a region with inflammatory infiltrate and a region with no inflammatory infiltrate. B. 
Quantification of the relative expression each immune cell marker in the inflammatory 
infiltrate. C. Quantification of the colocalization of MyH-PhD-05 with each immune cell 
marker. Fluorescent imaging: Blue: DAPI (nuclei), Green: FITC (CD4, CD68, and CD11b), 
and Red: Cy5 (MyH-PhD-05). Median values (horizontal line), 25% to 75% percentiles 
(box), and range of values (whiskers). CD4, CD68, and CD11b: n=4. One-way ANOVA 
(p<0.05) with Tukey’s multiple comparison test, *p<0.05, **p<0.01, ***p<0.001. 
 
4.2.8: Proteonomic Analysis 
For proteomic analysis, a total of 9 animals were used in the following treatment groups: 
animals immunized with MyH/CFA (n=7), and animals immunized with PBS/CFA (n=2). At 
21 days after initial immunization, animals were euthanized, and the hearts were dissected 
and flash frozen. Each heart was then homogenized and incubated with streptavidin 
conjugated paramagnetic particles (Magnesphere, Promega) functionalized with 
biotinylated MyH-PhD-05 (New England Peptide). The resulting magnetic beads were 
then removed, washed with PBS, frozen, and sent to the Emory Integrated Proteomics 
Core for processing and analysis. All the identified genes that showed at least a two fold 
increase in the number of peptide spectral matches in at least two animals from the 
MyH/CFA treatment group when compared to the PBS/CFA treatment group average 
were selected for enrichment analysis with ToppGene (https://toppgene.cchmc.org). A 
total of 75 genes met the criteria for selection (Appendix Table 1). Using ToppGene, the 
20 cellular components where at least 10% of the genes that met the selection criteria 
were present (i.e.: 8 proteins from input) were selected, and the –log10(p value) for each 
component was reported (Figure 32). These results suggests that MyH-PhD-05 is 
potentially binding to several different intracellular components. This could be due to 
uptake of MyH-PhD-05 by different cells, although it is more likely due to the binding of 
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the peptide to intracellular components released into extracellular space during 
inflammation present in myocarditis. Several cellular components and subsets of cellular 
components were identified more than once in enrichment analysis, such as different 
mitochondrial components (n=6), or different junctional components (n=5). Given that 
MyH-PhD-05 has homology with cytotoxic T lymphocyte lipase, it is interesting that several 
cellular components have high lipid content such as the myosin sheath, the mitochondrial 
envelope, the mitochondrial membrane, mitochondrial inner membrane, organelle inner 
membrane, and the cell surface. The presence of different junctions (cell junction, cell-
substrate junction, cell-substrate adherens junction, focal adhesions, adherens junctions, 
and anchoring junction) also suggests that MyH-PhD-05 targets proteins spanning from 
the cytoskeleton of the cell through the cell membrane.  
 
 
Figure 32: List of major cellular components identified through proteomic analysis. The top 
cellular components along the –log10(p value) are provided. Numbers in bars indicate the 





Myocarditis is one of the most challenging diagnosis in cardiology [9, 56, 59]. The gold 
standard for diagnosis, EMB, is invasive and has a high risk for serious complications [9, 
12, 53, 55-57, 59, 61]. Thus, there is interest in exploring noninvasive imaging modalities 
such as CMR, echocardiography and computerized tomography [102-107], and 
improvements to these imaging modalities are constantly being explored. For example, 
targeted molecular imaging using fluoride-19 in CMR and antibody coated microbubbles 
in echocardiography have shown improvements in the diagnosis of myocarditis [62, 64]. 
However, fluoride-19 is not specific to myocarditis and can be incorporated by 
macrophages and monocytes in other disease processes such as pneumonia, allograft 
rejection, cardiac ischemia, and cerebral ischemia; whereas the use of antibodies in 
therapies is limited by production costs, low tissue penetration, and host immune response 
to antibody [62, 63]. 
 
To address these potential limitations, we used in vivo phage display to identify potential 
targeting peptides for the diagnosis of myocarditis. Similar to other published in vivo phage 
display experiments [88-91], we performed a total of 3 pannings and identified 36 unique 
12 AA peptides (Figure 20). We then selected 6 of those peptides for ex vivo peptide 
screening experiments based on either the frequency each peptide came up or on BLAST 
and literature review suggesting each different peptide had a homology with different cell 
types involved in the immune response (Table 2). After ex vivo screening (Figure 21-25), 
we selected two peptides, MyH-PhD-05 and MyH-PhD-120, for in vivo peptide screening. 
Fluorescent imaging after IV delivery of these two peptides demonstrated that MyH-PhD-
05 (and to a lesser extent MyH-PhD-120) was able target animals with severe myocarditis 
in the absence of any functional changes (Figure 18, 27-30). We verified that MyH-PhD-
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05 was targeting inflammation specific to myocarditis by testing its ex vivo targeting 
potential in animal model of MI (Figure 26). We then used immunohistochemistry on 
animals with severe myocarditis to demonstrate that inflammatory infiltrates are 
predominantly CD4+ T cells, and that MyH-PhD-05 colocalizes with CD4+ T cells and 
monocytes (CD11b+) (Figure 31). Finally, we used proteomic analysis to show that MyH-
PhD-05 targets intracellular contents that are released to extracellular space during 
myocarditis (Figure 32). 
 
The animal model of EAM is only efficient in inducing myocarditis in 40-60% of animals 
immunized, and those animals usually have variable disease severity as determined by 
the degree of infiltration observed on H&E stained sections [62, 64, 93-99] (Figure 17). To 
account for this, we increased the number of animals in our treatment groups. For 
example, in the in vivo peptide screening study, a total of 36 animals were immunized with 
MyH/CFA before treatment with S-MyH-PhD-05. It is possible that with an increased 
number of animals a relationship similar to that observed for S-MyH-PhD-05 would 
emerge for animals treated with S-MyH-PhD-120 (n=12). Additionally, the protocols that 
are used to score animals for myocarditis and myocarditis severity vary among different 
reports [62, 64, 93-99]. These protocols are also subject to inter- and intra-observer 
variability in addition to investigator bias. To account for this, we selected a protocol similar 
to the ones that have been more recently published and all scoring was conducted and 
analyzed by investigators blinded to the animal’s treatment group [62, 64]. In keeping with 
prior studies, we were unable to show functional differences in cardiac function at 21 days, 
despite some animals having severe myocarditis. This is important as it shows that the 




In vivo phage display has been extensively used in different animal models [88-92]. 
Although the use of more than 3 pannings could aid in screening for peptides with stronger 
affinity for myocarditis, most protocols and studies suggest that using 3 pannings is 
appropriate. Furthermore, since only 40-60% of animals immunized with MyH/PhD were 
expected to develop myocarditis, we pooled together the hearts of animals for each of the 
four treatment groups. As a result, a total of 43 animals were used for these experiments 
and each additional panning would have been both resource and time intensive without 
necessarily providing better results. We also expected to see a preferential accumulation 
in the number of phages binding to the hearts of animals in the MyH PhD group in each 
subsequent panning when compared to the other treatment groups, but this was not 
observed (Table 1). This is probably due the variability present in the tittering process and 
the single data point present for each panning after pooling animals in the same treatment 
group together. Finally, only a handful of colonies were picked for sequencing for each of 
the four treatment groups. Of those colonies sequenced, we selected only 6 peptides for 
ex vivo screening (Table 2). It is possible that screening more colonies or selecting more 
peptides could have yielded other good candidates for targeting myocarditis, though 
screening so many candidates is both time and resource intensive. 
 
For our in vivo peptide screening experiments, we were unable to measure the level of 
fluorescent signal in the heart of animals when these animals were being imaged in vivo 
under anesthesia. This is probably due to the low penetrance of the fluorescent signal 
through tissue and the low levels of peptide present in focal regions with inflammatory 
infiltrates in animals with myocarditis. Thus, we presented ex vivo fluorescent data (Figure 
27-30). In future experiments, using higher concentrations of our peptide or conjugating 
our peptides to fluorescent molecules with higher wavelengths (i.e.: Streptavidin DyLight 
800) could yield better results. Due to the nature of our studies and the shortcomings in 
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fluorescent imaging, we were not able to perform longitudinal, long-term studies to 
determine predictive value, though that is also an important next step. 
 
While identifying the exact cell and protein that our peptides target is of great interests, it 
was difficult to determine using our immunohistochemistry analysis. The resolution of 
fluorescent microscopy is several hundred nanometers, making it difficult to determine if 
our peptide is binding to intracellular components, cell surface components, or 
extracellular components. We decided to use proteomic analysis to identify the potential 
binding partners of MyH-PhD-05, although future work can focus on using other 
techniques such as single cell flow cytometry and multiphoton imaging. Furthermore, our 
initial studies focused on screening for only three different cell types, CD4+ T cells, 
macrophage (CD68), and monocytes (CD11b). Future experiments will focus on screening 
for other cell types and markers that are present in inflammatory infiltrates of myocarditis, 
such as macrophages (F4/80), dendritic cells (CD11c), and granulocytes (Gr-1) [62, 64]. 
 
Proteomic analysis suggested that S-MyH-PhD-05 was binding to several different 
intracellular components. This could be due to uptake of phages containing MyH-PhD-05 
by different cells, although it is more likely due to the binding of the phages to intracellular 
components released into extracellular space during inflammation present in myocarditis. 
Several cellular components and subsets of cellular components were identified more than 
once in enrichment analysis, such as different mitochondrial components (n=6), or 
different junctional components (n=5). Given that MyH-PhD-05 has homology with 
cytotoxic T lymphocyte lipase, it is interesting that several cellular components have high 
lipid content such as the myosin sheath, the mitochondrial envelope, the mitochondrial 
membrane, mitochondrial inner membrane, organelle inner membrane, and the cell 
surface. The presence of different junctions (cell junction, cell-substrate junction, cell-
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substrate adherens junction, focal adhesions, adherens junctions, and anchoring junction) 
also suggests that MyH-PhD-05 targets proteins spanning from the cytoskeleton of the 
cell through the cell membrane.  
 
In summary, we were able to use in vivo phage display to identify and test potential 
targeting peptides for myocarditis. We identified one peptide, MyH-PhD-05, that targets 
severe myocarditis. Future studies will focus on better identification of its potential targets. 
For clinical applications, MyH-PhD-05 can be conjugated to other imaging agents to 
improve current diagnostic and therapeutic technologies. For example, MyH-PhD-05 
could be conjugated to microbubbles for echocardiography [64] or to gadolinium contrast 
agents for CMR, which have been used clinically in myocarditis [105, 108]. MyH-PhD-05 
can also be conjugated to different dendrimers or exosomes in order to deliver novel 
therapies such as CD40 siRNA, CCR2 siRNA, or P2X7 receptor antagonist [94, 109-112], 
and improve clinical outcomes. Additionally, when considering clinical applications of 
MyH-PhD-05, it is important to note that MyH-PhD-05 has similar homology in humans as 
mice (homology: lipase, pancreatic triacylglycerol lipase precursor, ryanodine receptor) 




CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS 
 
Cardiovascular disease (CVD) has accounted for more deaths than any other major cause 
of death in the United States every year since 1900, with the exception of 1918 [1]. Despite 
improvements in the management of CVD, there is still a need for new and improved 
treatments and diagnostics. In peripheral artery disease (PAD), treatment with pro-
angiogenic growth factors, such as vascular endothelial growth factor (VEGF), is currently 
being explored [4-6, 26]. However, there is a need to overcome limitations of this therapy, 
such as the growth factor’s short half-life, inadequate delivery to target tissue, and 
inadequate retention at target tissue [5, 7, 8, 19, 26, 33-35]. In myocarditis, a large number 
of patients go undiagnosed due to the disease’s heterogeneous etiology, pathophysiology, 
and clinical presentation [9, 12]. Current diagnostic techniques, such as endomyocardial 
biopsy and cardiac magnetic resonance, are inadequate, and there is a need for new 
technologies for the appropriate diagnosis and timely treatment of myocarditis. This 
dissertation aims to explore two different targeting techniques for the treatment and 
diagnosis of PAD and myocarditis. 
 
5.1: Targeted Delivery of VEGF for the Treatment of PAD 
 
5.1.1: Summary 
In this project we explored the use of a novel targeted delivery system using a modified 
Hoechst compound to target extracellular DNA in an animal model of PAD and deliver 
VEGFmp or VEGF165 to ischemic tissue. We successfully synthesized two different 
compounds, HoVEGFmp and HoVEGF165. After conjugation, we used a permeability 
assay to confirm that both compounds were cell impermeable but retained the ability to 
bind to extracellular DNA. We then used Western blot analysis and a tube formation assay 
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to demonstrate that our compounds retained their angiogenic activity, but these results 
were inconclusive. For in vivo studies, we used an animal model of hindlimb ischemia 
(HLI). Neither of compounds showed improvements in retention or targeting when 
compared to controls. 
 
5.1.2: Limitations 
The major limitation of this project is the rapid breakdown of our compounds in vivo. Blood 
plasma contains a number of different proteinases that can rapidly breakdown both 
peptides and proteins [82, 83]. Furthermore, in sites of inflammation there is an increase 
in the amount of proteinases that can breakdown any circulating peptides and proteins 
[82, 83]. In our retention studies, an inflammatory response to the femoral ligation surgery 
increases the levels of proteinases present at the injury site, which in turn leads to the 
rapid breakdown of both peptides (HoVEGFmp) and proteins (HoVEGF165). In our 
targeting studies, both of our compounds were broken down by proteinases present in 
blood plasma before reaching the target tissue. 
 
A second limitation of this project is the rapid breakdown and excretion of our compound 
through the kidneys. Both peptides (<5kDa) and small proteins (20kDa) are efficiently 
cleared by the kidneys, with renal clearance ratios of 1.0 and 0.5-0.8 respectively [82, 84, 
86]. Peptides are usually hydrolyzed by brush membrane proteinases, while proteins are 
collected in endocytic vacuoles that fuse with lysosomes and break down the proteins [82, 
84, 86]. In both our retention and targeting studies, our compounds were rapidly cleared 
through the renal system. Interestingly, we observed fluorescent signal in the anatomical 
area corresponding to the bladder for animals that were treated with HoVEGFmp, but not 
for animals treated with HoVEGF165. This suggests that our HoVEGFmp was being broken 
down in the brush border membrane of the kidneys, while HoVEGF165 was internalized 
93 
 
into endocytic vacuoles, where the fluorophore was probably broken down instead of 
being secreted through the renal system. 
 
Finally, for in vivo studies we used an animal model of HLI with BALB/c mice. BALB/c mice 
have been reported to have fewer or narrower collaterals when compared to C57BL/6 
mice [71]. Even though we would expect more severe ischemia and necrosis in BALB/c 
mice, the lack of collaterals limits the amount of compound that can be delivered to areas 
of ischemia and necrosis. 
 
5.1.3: Future Directions 
To circumvent the limitations of our compounds, we need to explore making certain 
modifications that increase the stability of our compounds in vivo. For example, some 
modifications that might increase the half-life of our peptide and protein based compounds 
include glycosylation, PEGylation, substitution of peptide cleavage sites, modification of 
secondary peptides structures, and binding to carrier proteins such albumin [82-85]. 
Perhaps one modification that can be easily explored is the conjugation of both our 
modified Hoechst compound and VEGFmp or VEGF165 to streptavidin (~50kDa). In our 
lab, streptavidin has been successfully conjugated to both peptides (Chapter 4) and 
proteins (Insulin Growth Factor-1 [23]) for in vivo studies. 
 
We also need to explore modifications to our animal model. For example, using C57BL/6 
mice instead BALB/c mice might provide more collaterals for our compound to be 
delivered to ischemic tissue. Furthermore, we can adjust the severity of ischemia by 
removing part of the femoral artery in order to induce more necrosis and release more 
DNA [113], although this might cause more inflammation at the surgery site. Finally, we 
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can also explore using animal models that better reflect the underlying atherosclerotic 
disease in patients with PAD, such as using ApoE knockout mice [114]. 
 
5.2: Identification of Targeting Peptides for the Diagnosis of Myocarditis 
 
5.2.1: Summary 
In this project, we identified a targeting peptide for the diagnosis and treatment of 
myocarditis. In an animal model of myocarditis, we used an in vivo phage display library 
to identify peptides that preferentially targeted diseased myocardium. We then did ex vivo 
screening on six of our potential peptides, successfully identifying two peptides whose 
binding correlated with disease severity. In vivo screening demonstrated that one peptide, 
MyH-PhD-05, was able to detect animals with severe myocarditis in the absence of 
functional changes. Immunohistochemistry was used to show that inflammatory infiltrates 
in myocarditis are predominantly CD4+ T cells, and that MyH-PhD-05 colocalizes with 
CD4+ T cells and monocytes (CD11b+). Finally, proteomic analysis was used to 
demonstrate that MyH-PhD-05 targets intracellular contents that are released to 
extracellular space during myocarditis.  
 
5.2.2: Limitations 
The animal model of myocarditis that we used is only efficient in inducing myocarditis in 
40-60% of animals immunized, and those animals usually have a variable severity of 
myocarditis [62, 64, 93-99]. To account for this, we increased the number of animals in 
our treatment groups. However, there is no way to determine beforehand how many 
animals will develop mild myocarditis or severe myocarditis. Furthermore, the protocols 
that are used to score animals for myocarditis and myocarditis severity vary among 
different reports [62, 64, 93-99]. These protocols are subject to inter- and intra-observer 
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variability. To account for this, all scoring was conducted and analyzed by investigators 
blinded to the animal’s treatment group. The cutoffs used to define mild myocarditis and 
severe myocarditis also vary between different reports. We used a cutoff similar to the 
ones employed by Steinl et al and van Heeswijk et al [62, 64], although we adjusted the 
cutoffs to account for the fact that animals that were not immunized at all sometimes 
showed small foci of leukocytes between cells (i.e.: H&E Sum Score ≤ 3). 
 
For in vivo phage display experiments, only a handful of colonies were picked for 
sequencing for each of the four treatment groups. Of those colonies sequenced, we 
selected only 6 peptides for ex vivo screening (Table 2). It is possible that screening more 
colonies or selecting more peptides could have yielded other good candidates for targeting 
myocarditis, though screening so many candidates is both time and resource intensive. 
 
For our in vivo peptide screening experiments, we were unable to measure a fluorescent 
signal in vivo. Thus, all the data presented in Chapter 4 is based on the ex vivo imaging 
done 10 minutes after treatment of animals with our targeting peptides. The use of higher 
concentrations of our peptides or conjugating our peptides to fluorescent molecules with 
higher wavelengths (i.e.: Streptavidin DyLight 800) could allow us to use in vivo imaging 
instead of ex vivo imaging. This would allow us to do long term longitudinal studies and to 
reduce the amount of animals used in our future experiments. 
 
Finally, the identification of the exact cell and protein that our peptides target is limited by 
the use of both immunohistochemistry and proteonomic analysis. The resolution of 
fluorescent microscopy is several hundred nanometers, making it difficult to determine if 
our peptide is binding to intracellular components, cell surface components, or 
extracellular components. Proteonomic analysis, on the other hand provides good 
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resolution of cellular components targeted, but not of specific proteins. Future work can 
focus on using other techniques such as single cell flow cytometry and multiphoton 
imaging that provide better resolution.  
 
5.2.3: Future Directions 
In the future, we will further explore the cells and proteins our peptides are targeting. In 
myocarditis, many different inflammatory cell populations play a role, such as leukocytes, 
T lymphocytes (helper T cells, cytotoxic T cells, Memory T cells, etc.) B-lymphocytes, 
macrophages, natural killer cells, and dendritic cells [54, 55, 58, 98, 115, 116]. 
Additionally, there is wide variety of cytokines, metalloproteases, and other proteins that 
are involved [94-96, 111, 112, 117]. We can use flow cytometry and multiphoton imaging 
to identify the cell populations and proteins that our peptides target. 
 
We can also conjugate our peptides to improve current diagnostic technologies. For 
example, our peptides could be conjugated to microbubbles for echocardiography [64, 
118], or to gadolinium contrast agents for MRI [108, 119, 120]. We can also conjugate our 
peptides to different dendrimers or exosomes in order to deliver novel therapies such as 
CD40 siRNA, CCR2 siRNA, or P2X7 receptor antagonist [94, 109-112].  
 
Finally, when considering clinical applications of peptides, it is important to note that our 
peptide MyH-PhD-05 has similar homology in humans as mice (human homology: lipase, 
pancreatic triacylglycerol lipase precursor, ryanodine receptor) and thus future studies can 







A.1: Methods for Peripheral Artery Disease Project 
 
A.1.1: Synthesis of Compounds 
 
A.1.1.1: Synthesis of HoVEGFmp 
VEGFmp (MW = 3166.9g/mol, Anaspec) was resuspended in deionized water to a molarity 
of 1nmol/µL. Hoechst-thiopyridyl (MW = 751.96g/mol, Niren Murthy Lab) was 
resuspended in deionized water to a molarity of 1.86nmol/µL. Equimolar amounts of each 
compound were mixed together in addition to PBS/EDTA to the final desired molarity. For 
example, 25nmol of each reagent plus PBS/EDTA were mixed to a final volume of 50µL 
to synthesize a compound with a molarity of 0.5nmol/µL. The reaction was allowed to 
proceed for 3 hours at room temperature. Using a Slide-A-Lyzer Mini Dialysis Unit with a 
2kDa molecular weight cut off (Thermo Scientific #69580), the resulting compound was 
then dialyzed three times in 50mL of PBS/EDTA. The first two dialysis were for 2 hours at 
room temperature, and the third dialysis was overnight in a cold room (2-8°C). A Bradford 
Assay was used to determine the final concentration. 
 
A.1.1.2: Synthesis of HoVEGF165 
Human recombinant VEGF165 (MW = 19,165g/mol, Cell Signaling #8065) was 
resuspended in sterile PBS to a final concentration of 1000µg/mL. The DyLight 800 
Microscale Antibody Labelling Kit (Thermo Scientific #53063) was then used as instructed 
to fluorescently label the protein (VEGF165-Dy). We then used a Bradford Assay to 
determine our protein yield (i.e.: in one batch, the yield was 88.53% with a VEGF165 
concentration of 995.45µg/mL and a VEGF165-Dy concentration of 881.25µg/mL). For 
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further conjugation calculations, we assumed VEGF165-Dy was conjugated to at least one 
fluorophore (MW=1050g/mol) and had a MW of 20,215g/mol. Hoechst-thiopyridyl (MW = 
751.96g/mol) was resuspended in deionized water to a molarity of 0.337nmol/µL. For 
every 1nmol of VEGFG165-Dy, 20nmol of Hoechst-thiopyridyl were added in addition to 
PBS/EDTA to a final molarity of 0.0109nmol/µL. The reaction was allowed to proceed for 
3 hours at room temperature. Using a Slide-A-Lyzer Mini Dialysis Unit with a 2kDa 
molecular weight cut off (Thermo Scientific #69580), the resulting compound was then 
dialyzed three times in 50mL of PBS/EDTA. The first two dialysis were for 2 hours at room 
temperature, and the third dialysis was overnight in a cold room (2-8°C). A Bradford Assay 
was used to determine the final concentration. 
 
A.1.2: Methods for In Vitro Studies 
 
A.1.2.1: Permeability Assay 
 
A.1.2.1.1: HoVEGFmp 
Cardiomyocyte progenitor cells were isolated from the hearts of adult male Sprague-
Dawley rats by selection of c-Kit+ cells with anti-cKit antibody (H-300, Santa Cruz) coated 
magnetic beads (Dynal) as previously described [121]. CPC growth media consisted of 
Ham’s F12 media, 10% Fetal Bovine Serum (FBS), basic Fibroblast Growth Factor 
(10ng/mL), Leukemia Inhibitory Factor (10ng/mL), Penicillin/Streptomycin (100 Units/mL, 
100µg/mL), and L-Glutamine (2mM). 10,000 cells were plated on 4 different wells of a 96 
well plate and allowed to grow for 2 days. For fixed cells (2 wells), 100µL of ice cold 
methanol was added to each well for 10 minutes. The methanol was then removed and 
each well (including 2 wells with live cells) was washed with 100µL of CPC growth media. 
A total of 100µL of treatment (2.00 x 10-6M of either Hoechst-thiopyridyl or HoVEGFmp in 
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CPC growth media) was then added to each respective well for 20 minutes. Treatments 
were then removed, and 50µL of Hank’s Balanced Salt Solution was added to each well. 
Each well was then imaged using fluorescent microscopy with a DAPI filter. 
 
A.1.2.1.2: HoVEGF165 
Immortalized mouse aortic endothelial cells (iMAECs) were received from the Hanjoong 
Jo Lab. iMAEC growth media consisted of DMEM, ECGS (Sigma #E2759, 50µg/mL), 
MNEAA (GIBCO #11140-050), 10% FBS, and Penicillin/Streptomycin (100Units/mL, 
100µg/mL). 50,000 cells were plated on 6 different wells of a 24 well plate and allowed to 
grow for 2 days. For fixed cells (3 wells), 200µL of ice cold methanol was added to each 
well for 10 minutes. The methanol was then removed and each well (including 3 wells with 
live cells) was washed with 200µL of iMAEC growth media. A total of 200µL of treatment 
(2000ng/mL of Hoechst 33258, 2000ng/mL of Hoechst-thiopyridyl or 500ng/mL of 
HoVEGF165 in iMAEC growth media) was then added to each respective well for 20 
minutes. Treatments were then removed, and 200µL of Hank’s Balanced Salt Solution 
was added to each well. Each well was then imaged using fluorescent microscopy with a 
DAPI filter. 
 
A.1.2.2: Western Blot Analysis 
iMAECs were received from the Hanjoong Jo Lab. iMAEC growth media consisted of 
DMEM, ECGS (Sigma #E2759, 50µg/mL), MNEAA (GIBCO #11140-050), 10% FBS, and 
Penicillin/Streptomycin (100Units/mL, 100µg/mL). Once confluent, cells were starved for 
5-6 hours in starving media, which includes DMEM, MNEAA, and Penicillin/Streptomycin. 
Treatments of HoVEGFmp and VEGFmp were made to a final molarity of 1.00 x 10-6 in 
starving media. After 5-6 hours, starving media was removed and replaced with the 
appropriate treatment of either HoVEGFmp or VEGFmp. At the appropriate time point (1, 
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5, 10, or 30 minutes after treatment), the treatment was removed, and cell lysis buffer was 
added. Lysates were then removed from each well, pipetted into an Eppendorf tube and 
placed in the cold room overnight. Bradford was preformed to determine the protein 
concentration of each lysate. For Western Analysis, 40µg of protein were loaded into each 
lane, and a standard protocol was followed. Antibodies for pERK1/2 (Cell Signaling 
#9101S) and ERK1/2 (Cell Signaling #9102S) were used and bands were analyzed using 
ImageJ. 
 
A.1.2.3: Tube Formation 
Rat Cardiac endothelial cells (CECs) were thawed from previous stocks in the Davis Lab. 
CEC growth media was made using the Complete Rat Endothelial Cell Media Kit (Cell 
Biologics #M1266). Growth media consisted of suggested ratios of kit contents: EGF, FBS 
(2%), L-Glutamate, Antibiotic/Antimycotic, and CEC Base Media. After the cells were 
confluent, they were placed in starving media (0.4% FBS) overnight. All treatments 
(500ng/mL of VEGF165, VEGF165-Dy, and HoVEGF165) were made in Insulin Transferrin 
Selenium (ITS) media, which included the same components of growth media but ITS was 
used to replace FBS. The starving media was replaced with the appropriate treatment 
(1mL per well in a 6 well plate) for 24 hours. After treatment, the cells were removed and 
from their respective wells using TrypLE (Thermo Scientific), and 30,000 cells/cm2 were 
placed on each well of a 96 well plate covered with Geltrex (Thermo Scientific). After six 
hours, 50µL of 4µM Calcein was added to each well and left to incubate for 15 minutes. 






A.1.3: Animal Models 
 
A.1.3.1: Hindlimb Ischemia 
Male BALB/c mice were anesthetized with 1-3% isoflurane, intubated, and placed on a 
heating pad (37°C). Hair was removed from both hindlimbs using Nair hair removal lotion. 
On the left hindlimb, a small incision (5mm) was made beginning at the inguinal crease 
along the femoral vessels that are visible through the skin. At the origin of the deep femoral 
artery, the nerve, artery, and vein were gently separated to avoid injury. The first ligation 
of the femoral artery was done at this site. Similar procedure was used to separate the 
femoral nerve, artery, and vein at the knee level of the exposed hindlimb, where the 
saphenous artery originates. A second ligation of the femoral artery was done at this site. 
Animals were allowed to recover for 1 day before undergoing Laser Doppler Perfusion 
Imaging for functional assessment or receiving appropriate treatments.  
 
A.1.3.2: Myocardial Infarction 
Myocardial infarction was performed on male C57BL/6 mice. Briefly, mice were 
anaesthetized (1-3% isoflurane), intubated and heat exposed by separation of ribs. The 
left anterior descending (LAD) coronary artery was ligated for 30 minutes. Animals were 
then closed and allowed to recover for 1 day before receiving appropriate treatments. 
 
A.1.4: Methods for In Vivo Studies 
 
A.1.4.1: SYBR Gold Nucleic Assay Gel Stain 
Blood was extracted from each animal (20µL) by nicking their tail and collecting blood in 
sterile capillary tubes containing EDTA at different time points (2, 24, and 48 hours after 
surgery). After 30-60 minutes, samples were spun at 2,000 x g for 5 minutes and the 
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supernatant (serum) was removed and placed in a new Eppendorf tube. SYBR Gold 
Nucleic Acid Gel Stain (Thermo Fisher Scientific #S11494) was used as indicated to 
measure DNA concentrations using a plate reader (Excitation / Emission: 485nm/528nm) 
and a single stranded DNA standard. 
 
A.1.4.2: Fluorescent Imaging 
In vivo and ex vivo Fluorescent imaging was performed using either the Xenogen IVIS 100 
imaging system or the In Vivo Xtreme Imaging system. For in vivo imaging, animals were 
anesthetized using 1-3% isoflurane, and each individual mouse was imaged using 
appropriate filters and exposures. For ex vivo imaging, organs were imaged immediately 
after dissection using appropriate filters and exposures. Fold change in fluorescent signal 
relative to control tissue was reported for each region of interest. In animals undergoing 
hindlimb ischemia, the contralateral hindlimb was used as the control tissue. In animals 
with EAM, the spleen was used as the control tissue. 
 
A.1.4.3: Homogenization of Tissue 
We weighed the tissue to be homogenized. For every 1mg of tissue, 3-5mL of lysis buffer 
(with protease and phosphatase inhibitors) were added. Tissue was homogenized and left 
in the cold room overnight. The next day samples were centrifuged at 13,000 x g for 10 
minutes, and the supernatant was removed and placed in a new Eppendorf Tube. 
Bradford was performed to determine the protein concentration. 
 
A.1.4.4: Immunoprecipitation 
For immunoprecipitation, 100µg of protein were incubated with VEGFR-2 Antibody 
overnight in a cold room. 20µL of appropriate microbeads were then added to each 
samples, and the samples were incubated for 2 hours. Samples were then centrifuged at 
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2,500 x g for 5 minutes, and the supernatant was removed. To elute the proteins, 30µL of 
Laemeli dye was used and Westerns were run using VEGFR-2 and p-tyrosine kinase 
antibodies. 
 
A.1.5: Statistical Analysis 
All statistical analysis were performed using GraphPad Prism 5. All data are expressed as 
Mean ± SEM. To determine significance, either a One-way or Two-way analysis of 
variance (ANOVA) were performed, followed by Tukey multiple comparisons test or 
Bonferroni post hoc test. For correlations, a linear regression was done followed by a 





A.2: Methods for Myocarditis Project 
 
A.2.1: Animal Models 
 
A.2.1.1: Animal Model of Experimental Autoimmune Myocarditis 
All animal experiments were performed with the approval of the Emory University 
Institutional Animal Care and Use Committee. A total of 146 male BALB/c mice (6-8 weeks 
old) were used in this study and were divided as follows: 43 Animals for phage display, 31 
for ex vivo analysis, 63 for in vivo analysis and immunohistochemistry, and 9 for proteomic 
analysis. To induce experimental autoimmune myocarditis (EAM), mice were anesthetized 
using 1-3% isoflurane (Piramal) and injected subcutaneously at 0 and 7 days with 150µg 
of myosin heavy-chain α peptide (MyH: Ac-SLKLMATLFSTYASAD-OH, New England 
Peptide) dissolved in 100µL of PBS and emulsified with 100µL of complete Freund’s 
adjuvant (CFA, Sigma) [62, 64, 93-99]. For control animals, animals were either injected 
subcutaneously at 0 and 7 days with 100µL of PBS emulsified in 100 µL of CFA, or 
received no treatment. In this model, 40-60% of animals develop myocarditis with variable 
severity [62, 64, 93-99]. This phenotype is characterized by the presence of inflammation 
within 10 days after initial immunization, which peaks around day 21 and is cleared by day 
56 [55, 99]. 
 
Each treatment dose was prepared the day before by mixing the MyH or PBS with CFA, 
capping the mixture tightly, and vortexing it overnight in the cold room. One the day of 
treatment, the emulsion was drawn up using glass syringes and 18-G needles and 
thoroughly mixed. After removing the air, the 18-G needles were replaced with a 25-G 
needle, and emulsion was injected subcutaneously onto the back of anesthetized animals. 
105 
 
A.2.1.2: Animal Model of Myocardial Infarction 
All animal experiments were performed with the approval of the Emory University 
Institutional Animal Care and Use Committee. A total of 2 adult male C57BL/6 mice (>8 
weeks old) were subjected to myocardial infarction (MI) in this study. Briefly, the animals 
were anesthetized using 1-3% isoflurane (Piramal), and after tracheal intubation, the 
hearts were exposed by separation of the ribs. Myocardial infarction was induced by the 
permanent ligation of the left anterior descending coronary artery [100, 101]. The chest 
was then closed and the animals were allowed to recover. After 3 days, when extensive 
infiltration of inflammatory cells is expected [101], the hearts were removed and processed 
into frozen sections for immunohistochemistry and immunofluorescence as described 
below. 
 
A.2.2: In Vivo Phage Display 
A total of 43 animals were used for in vivo phage display. The experimental setup is similar 
to what has been previously described and is shown in Figure 20 [88-91]. A total of 3 
cycles or pannings were performed, similar to other published in vivo phage display 
experiments.[88-91] Briefly, at day 21 after induction of EAM, animals were anesthetized 
using 1-3% isoflurane (Piramal) and received an intravenous (IV) injection through the tail 
vein with either a linear 12 amino acid (AA) peptide phage library (Ph.D. 12 Phage Display 
Peptide Library Kit, New England BioLabs, #E8110S) or an empty phage (M13KE, New 
England BioLabs, #EN0316S) at a concentration of 1x109 plaque-forming units (pfu)/µL of 
PBS (110µL total volume). For each panning, animals were divided into the following 
treatment groups: MyH PhD: immunized with MyH/CFA and injected with the phage library 
(n=5 per panning); MyH Cont: immunized with MyH/CFA and injected with the control 
phage (n=4-5 per panning); PBS PhD: immunized with PBS/CFA and injected with the 
phage library (n=2-3 per panning); and PBS Cont: immunized with PBS/CFA and injected 
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with the control phage (n=2 per panning). After allowing the phage to circulate for 10 
minutes, animals were euthanized with CO2 and the hearts were excised, washed 
extensively in PBS and flash frozen.  
 
A.2.2.1: Phage Amplification 
The hearts for each of the four treatment groups were then weighed, pooled together, and 
homogenized in DMEM (Sigma) with protease inhibitors (Sigma) and phosphatase 
inhibitors (Sigma) at 1g of tissue per 1-4mL of DMEM solution. Each homogenate was 
then centrifuged at 2400xg and the pellet was re-suspended in DMEM solution. 
 
ER2738 Bacteria was streaked out on LB plates with tetracycline, and incubated at 37°C 
overnight. For phage amplification, 20mL of LB medium were placed in an Erlenmeyer 
flask and inoculated with a single ER2738 colony for each treatment group. Bacteria was 
allowed to grow until early-log (~2 hours). A total 400µL of the homogenate for each 
treatment group was added to each corresponding Erlenmeyer flask, and the bacteria was 
allowed to grow until mid-log (~4 hours). The resulting culture was placed in a centrifuge 
tube and spun for 10 minutes at 12,000 x g at 4°C. The resulting supernatant was 
transferred to fresh centrifuge tube and spun for 10 minutes at 12,000 x g at 4°C. The 
pellet was discarded and the supernatant was mixed with 1/6 volume of 20%PEG/2.5M 
NaCl and incubated overnight in the cold room in order to precipitate the phage. 
 
The resulting solution for each treatment group was spun at 12,000g for 15 minutes at 
4°C. The supernatant was discarded and the remaining pellet was resuspended in 1mL of 
TBS. The solution was re-spun and precipitated with 20%PEG/2.5M NaCl one more time 
in order to ensure no contamination was found. At the end, the resulting pellet was 
resuspended in 200µL of TBS. 
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A.2.2.2: Phage Titering 
For phage titering, 5-10mL of LB were inoculated with a single colony of ER2738 Bacteria 
and allowed to grow for 4-8 hours. For each treatment group, serial dilutions of the purified 
phage in LB were made ranging from 103 to 1011. A total of 200µL of ER2730 were infected 
with 10µL of each phage dilution for each treatment group and incubated for 5 minutes. 
The infected cells were then placed in tubes containing 45°C Top Agar and poured on pre-
wared LB/IPTG/Xgal plates. The plates were incubated overnight at 37°C. The next day, 
blue plaques were counted on plates with at least 100 blue plaques, and the resulting 
number was multiplied by the dilution factor to give us the total number of plaque forming 
unites (pfu) per 10µL. For each subsequent panning, you want to make sure that each 
animal is injected with a similar number of pfu intravenously. The phages isolated in 
panning 1 were injected at 1x109pfu/µL of PBS (110µL total volume) to animals in the 
same treatment group in panning 2, and the phages isolated in panning 2 were injected 
at 1x109 pfu/µL of PBS (110µL total volume) to animals in the same treatment group in 
panning 3.  
 
A.2.2.3: DNA sequencing 
After panning 3, a total of 110 colonies for MyH PhD, 16 colonies for MyH Cont, 110 
colonies for PBS PhD, and 16 colonies for PBS Cont were selected for DNA sequencing. 
Each colony was amplified by polymerase chain reaction (PCR) using unique primers 
based on the sequence of M13KE: (1) forward/sense: CACCGTTCATCTGTCCTCTTTC, 
and (1) reverse/antisense: TCACCGTACTCAGGAGGTTTAG (Integrated DNA 
Technologies). The sequence for each 12 amino acid linear peptide was found in the 
amplicon created by this primers. Colonies for each treatment group were picked by 
tapping them with a 10µL tip and pipetting up and down into 40µL of sterile water. The 
resulting colonies were then incubated at 95°C for 5 minutes, and spun at 3800 x g for 10 
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minutes. A total of 1µL each colony solution was amplified for 30-40 cycles using PCR 
and the primers described above. The presence of the amplicon was verified using a 1% 
agarose gel with SYBER Safe DNA Gel Stain (Invitrogen). The PCR products were then 
cleaned up with a QIAquick 96 PCR Purification Kit (Qiagen) according to manufacturer’s 
instructions. Nanodrop 2000c (Thermo Fisher Scientific) was used to quantify the DNA 
concentration of each amplicon, and the DNA sequence was generated by a DNA 
sequencer (Eurofins). The peptide sequences were determined using BioEdit Sequence 
Alignment Editor and further analyzed for homology to known proteins by searching NIH 
online databases. 
 
A.2.3: Histology, Immunohistochemistry, and Immunofluorescence 
At day 21 after induction of EAM, animals were euthanized using CO2 and the following 
organs were dissected: heart, lungs, liver, spleen, kidney, and thigh muscle. Similarly, at 
3 days after induction of MI, animals were euthanized using CO2 and the hearts were 
dissected. To make frozen sections, immediately after dissection samples were placed in 
OCT compound, frozen with liquid nitrogen, and stored at -80°C. Each sample was then 
sliced (8µm sections) and the resulting sections were stored at -80°C until use. Before any 
staining was performed, frozen sections were fixed with ice cold acetone for 5 to 10 
minutes. Only frozen sections were made for both animals that underwent MI. To make 
paraffin embedded sections, immediately after dissection samples were placed in 10% 
Formalin for 24 hours, and then in 70% ethanol at 4°C for 5 to 7 days until they were 
paraffin embedded. Each sample was then sliced (5µm sections) and the resulting 
sections were stored at room temperature until use. Before any staining, two 5 minute 
Histoclear washes were used to remove the paraffin, and the tissue was then rehydrated 
through serial 2 minute washes in decreasing concentrations of ethanol (100%, 90%, 70%, 




For the assessment of myocarditis severity, frozen and paraffin embedded heart sections 
were stained with hematoxylin (Thermo Fisher Scientific) and eosin (Thermo Fisher 
Scientific) (H&E) and mounted with Cytoseal. Each section was then imaged using 
NanoZoomer SQ (Hamamatsu) and scored for disease severity by investigators blinded 
to each animal’s treatment group in a manner similar to previous reports [62, 64]. Briefly, 
the left ventricle (LV) was divided into four quadrants. Each quadrant and the right ventricle 
(RV) were then scored on a scale of 0 to 4, with 0 representing no inflammatory infiltrates, 
1 representing small foci of leukocytes between cells, 2 representing larger foci of > 100 
leukocytes, 3 representing >10% of the quadrant cross section involved with inflammatory 
infiltrates, and 4 representing >30% of the quadrant cross section involved with 
inflammatory infiltrates. The sum of the scores for each LV quadrant and the RV (H&E 
Sum Score) was then used to classify the severity of myocarditis as follows: no 
myocarditis: H&E Sum Score ≤ 3; mild myocarditis: 4 ≤ H&E Sum Score ≤ 7; and severe 
myocarditis: H&E Sum Score ≥ 8. 
 
For assessment of the targeting potential of the peptides identified, custom peptides of 
each sequence (Table 1) were made with the following modifications: an LC Biotin on the 
N-terminus, and an amide on the C-terminus (New England Peptide). After fixation with 
acetone, frozen sections were incubated with proteinase K (5µg/mL in PBS, Thermo 
Fisher Scientific) for 15 minutes at room temperature, blocked with 5% bovine serum 
albumin (BSA) for 1 hour at room temperature, incubated with biotinylated peptides 
(10µg/mL in PBS, New England Peptide) for 1 hour at room temperature, and incubated 
with Streptavidin DyLight 650 (10µg/mL in PBS, Thermo Fisher Scientific) for 1 hour at 
room temperature in the dark. Nuclei were then stained with DAPI (1µg/mL in PBS) for 10 
minutes at room temperature before mounting using Prolong Gold Antifade Reagent 
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(Invitrogen). Fluorescent imaging of each section was then performed using an Olympus 
IX71 fluorescent microscope. Each section was then scored for the presence of targeting 
peptides by investigators blinded to each animal’s treatment group in a similar fashion to 
the H&E disease severity scoring previously described. Briefly, the LV was divided into 
four quadrants. Each quadrant and the RV were then scored on a scale of 0 to 3, with 0 
representing no stained cells, 1 representing few scattered stained cells, 2 representing 
the presence of a few stained foci, and 3 representing the continuous presence of stained 
tissue. The sum of the scores for each LV quadrant and the RV (Sum Score of peptide) 
was used to assess the degree of staining of each peptide, with a Sum Score of peptide 
> 2 being considered as positive staining.  
 
For assessment of inflammatory infiltrate cell types and the colocalization of these cell 
types with peptide MyH-PhD-05, frozen sections of the hearts of mice with severe 
myocarditis were used. After fixation with acetone, frozen sections were incubated with 
proteinase K (5µg/mL in PBS, Thermo Fisher Scientific) for 15 minutes at room 
temperature, blocked with 5% BSA for 1 hour at room temperature, and incubated with 
either CD4 (1:100 dilution in 5% BSA, Bio-Rad Laboratories, MCA4635), CD68 (1:100 
dilution in 5% BSA, Bio-Rad Laboratories, MCA1957), or CD11b (1:100 dilution in 5% 
BSA, eBioscience, 14-0112-81) at 4°C overnight. All sections were then incubated in Goat 
Anti-Rat Alexa Fluor 488 secondary antibody (1:200 dilution in 5% BSA, Thermo Fisher 
Scientific, A-11006) for one hour at room temperature in the dark, blocked with 5% BSA 
for 1 hour at room temperature in the dark, incubated with MyH-PhD-05 biotinylated 
peptide (100µg/mL in 5% BSA, New England Peptide) for 1 hour at room temperature in 
the dark, and incubated with Streptavidin DyLight 650 (10µg/mL in 5% BSA, Thermo 
Fisher Scientific) for 1 hour at room temperature in the dark. Nuclei were then stained with 
DAPI (1µg/mL in PBS) for 10 minutes at room temperature before mounting using Prolong 
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Gold Antifade Reagent (Invitrogen). Fluorescent images were acquired using an Olympus 
IX70 fluorescent microscope. Relative fluorescence from CD4, CD68, and CD11b labeling 
within inflammatory cell infiltrate of similar sections was measured using Fiji software 
(Version 1.51n) to calculate the sum of the pixel values and presented as relative light 
units (RLU). Colocalization analyses between each inflammatory cell marker and MyH-
PhD-05 were performed with Fiji software (Version 1.51n) using the Coloc2 function to 
obtain the Pearson’s R value. For each animal, 2 to 3 different fields were analyzed and 
the average value was reported. 
 
Finally, for the assessment of the targeting potential of MyH-PhD-05 to animals with MI, 
the frozen sections of the hearts of two animals that underwent MI were used. After fixation 
with acetone, frozen sections were incubated with proteinase K (5µg/mL in PBS, Thermo 
Fisher Scientific) for 15 minutes at room temperature, blocked with 5% BSA for 1 hour at 
room temperature, incubated with MyH-PhD-05 biotinylated peptide (100µg/mL in 5% 
BSA, New England Peptide) for 1 hour at room temperature, and incubated with 
Streptavidin DyLight 650 (10µg/mL in 5% BSA, Thermo Fisher Scientific) for 1 hour at 
room temperature in the dark. Nuclei were then stained with DAPI (1µg/mL in PBS) for 10 
minutes at room temperature before mounting using Prolong Gold Antifade Reagent 
(Invitrogen). Fluorescent imaging of each section was then performed using an Olympus 
IX70 fluorescent microscope. 
 
A.2.4: Peptide Conjugation for In Vivo Delivery 
To assess the in vivo targeting potential of peptides identified, either biotinylated MyH-
PhD-05 (New England Peptide, MW = 1762g/mol, 1µg/µL) or biotinylated MyH-PhD-120 
(New England Peptide, MW = 1791g/mol, 1µg/µL) were incubated with Streptavidin 
DyLight 650 (Thermo Fisher Scientific, MW = 55,649g/mol, 1µg/µL) at a 5:1 molar ratio in 
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PBS at 37°C for 3 hours in the dark. Assuming that four biotinylated peptides bound to 
each streptavidin, our target for each conjugation reaction was to produce 400µL of 
compound at a concentration of 400µg/mL. Using a dialysis unit with a 10kDa molecular 
weight cutoff (Microcon Ultracel), the resulting compound was then dialyzed three times 
for one hour in 500mL of PBS. Nanodrop 2000c (Thermo Fisher Scientific) was used to 
determine the final concentration of each resulting compound: S-MyH-PhD-05, and S-
MyH-PhD-120. Compounds were stored at -20°C until use. 
 
A.2.5: Ex Vivo Fluorescent Imaging 
A total of 63 animals were used for ex vivo fluorescent imaging. Briefly, 21 days after 
induction of EAM, each animal received an IV tail vein injection containing 1100ng of either 
S-MyH-PhD-05 (n=43) or S-MyH-PhD-120 (n=20) in a total volume of 110µL of PBS. 
Fifteen minutes after IV injection, animals were euthanized by CO2, and the heart, lungs, 
liver, spleen, kidney, and thigh were dissected and immediately imaged using the In Vivo 
Xtreme Imaging System (Bruker). Fold change in fluorescent signal relative the spleen 
was reported for each organ of interest. 
 
A.2.6: Echocardiography 
Animals were anesthetized using 1-3% isoflurane (Piramal). To assess cardiac function, 
echocardiography (Vevo 3100 with a MX550D, 22-55MHz probe) was performed prior to 
sacrifice. All functional evaluations were conducted and analyzed by investigators blinded 
to the animal’s treatment group. 
 
A.2.7: Proteomic Analysis 
A total of 9 animals were used in the following treatment groups: animals immunized with 
MyH/CFA (n=7), and animals immunized with PBS/CFA (n=2). At 21 days, animals were 
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euthanized using CO2 and the hearts were dissected and flash frozen. Each heart was 
then weighted and homogenized in NP40 buffer (Thermo Fisher Scientific) with protease 
inhibitors (Sigma) and phosphatase inhibitors (Sigma) at 1g of tissue per 1-4mL of NP40 
solution. The homogenate was then centrifuged, the pellet discarded, and the 
concentration measured using a Bradford protein assay (Bio-Rad). Streptavidin 
conjugated paramagnetic particles (SA-PMPs) (Magnesphere, Promega) were then 
functionalized with biotinylated MyH-PhD-05 (New England Peptide) according to 
manufacturer’s instructions to a final concentration of 1mg/mL in NP40. For each 
homogenate, 1000µg of protein were incubated with 100µg of functionalized SA-PMPs for 
1.5 hours. After 2 washes with NP40 buffer and 1 wash with PBS, the beads were frozen 
and sent to Emory Integrated Proteomics Core. 
 
At the Proteomics Core, samples were first homogenized as follows. All samples were 
vortexed in 300 µL of urea lysis buffer (8M urea, 100 mM NaHPO4, pH 8.5), including 3 
µL (100x stock) HALT protease and phosphatase inhibitor cocktail (Pierce). Next, the 
samples were briefly centrifuged for 1 minute at 12000 g. Each solution was then treated 
with 1 mM dithiothreitol (DTT) at 25°C for 30 minutes, followed by 5 mM iodoacetimide 
(IAA) at 25°C for 30 minutes in the dark. Protein was then digested with 1:50 (w/w) lysyl 
endopeptidase (Wako) at 25°C overnight. Samples were further digested overnight with 
1:50 (w/w) trypsin (Promega) at 25°C. Resulting peptides were desalted with a Sep-Pak 
C18 column (Waters) and dried under vacuum.  
 
Derived peptides were then resuspended in 10 µL of loading buffer (0.1% formic acid, 
0.03% trifluoroacetic acid, 1% acetonitrile). Peptide mixtures (2 µL) were separated on a 
self-packed C18 (1.9 µm Dr. Maisch, Germany) fused silica column (25 cm x 75 µM 
internal diameter (ID); New Objective) by a Water’s NanoAcquity and monitored on a Q-
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Exactive Plus Orbitrap (Thermo Fisher Scientific). Elution was performed over a 100 
minute gradient at a rate of 250 nL/minute with buffer B ranging from 3% to 80% (buffer 
A: 0.1% formic acid in water, buffer B: 0.1 % formic in acetonitrile, both with 5% DMSO). 
The mass spectrometer (MS) cycle was programmed to collect at the top 10 mode. The 
MS scans (300-1800 m/z range, 1,000,000 AGC, 100 ms maximum ion time) were 
collected at a resolution of 70,000 at m/z 200 in profile mode and the HCD MS/MS spectra 
(17,500 at m/z 200, 2 m/z isolation width, 30% collision energy, 50,000 AGC target, 50 ms 
maximum ion time). Dynamic exclusion was set to exclude previous sequenced precursor 
ions for 30 seconds within a 10 ppm window. Precursor ions with +1, and +8 or higher 
charge states were excluded from sequencing. 
 
Spectra were searched using Proteome Discoverer 2.1 against mouse Uniprot database 
(53,289 target sequences). Searching parameters included fully tryptic restriction and a 
parent ion mass tolerance (± 20 ppm) and a product mass tolerance of 0.05 dalton. 
Methionine oxidation (+15.99492 Da), asaparagine and glutamine deamidation (+0.98402 
Da) and protein N-terminal acetylation (+42.03670) were variable modifications (up to 3 
allowed per peptide); cysteine was assigned a fixed carbamidomethyl modification 
(+57.021465 Da). Percolator was used to filter the peptide spectrum matches to a false 
discovery rate of 1%. 
 
All genes that showed at least a two fold increase in the number of peptide spectral 
matches in at least two animals from the MyH/CFA treatment group when compared to 
the PBS/CFA treatment group average were selected for enrichment analysis (Appendix 





A.2.7.1: List of Genes for Enrichment Analysis 
Appendix Table 1: List of genes used for enrichment analysis. 
# Protein 
1 ACADL (acyl-CoA dehydrogenase, long chain) 
2 ACOT1 (acyl-CoA thioesterase 1) 
3 ACOT2 (acyl-CoA thioesterase 2) 
4 ADH5 (alcohol dehydrogenase 5 (class III), chi polypeptide) 
5 AKR1B1 (aldo-keto reductase family 1 member B) 
6 ANXA6 (annexin A6) 
7 APOA1 (apolipoprotein A1) 
8 CKB (creatine kinase B) 
9 CMYA5 (cardiomyopathy associated 5) 
10 COX7C (cytochrome c oxidase subunit 7C) 
11 CPSF6 (cleavage and polyadenylation specific factor 6) 
12 CPT2 (carnitine palmitoyltransferase 2) 
13 CRAT (carnitine O-acetyltransferase) 
14 CSRP1 (cysteine and glycine rich protein 1) 
15 DDX46 (DEAD-box helicase 46) 
16 DECR1 (2,4-dienoyl-CoA reductase 1) 
17 DES (desmin) 
18 EDC4 (enhancer of mRNA decapping 4) 
19 ENO1 (enolase 1) 
20 ENO3 (enolase 3) 
21 ETFDH (electron transfer flavoprotein dehydrogenase) 
22 FABP3 (fatty acid binding protein 3) 
23 FABP4 (fatty acid binding protein 4) 
24 FGA (fibrinogen alpha chain) 
25 FGG (fibrinogen gamma chain) 
26 GDI2 (GDP dissociation inhibitor 2) 




28 GNAI2 (G protein subunit alpha i2) 
29 GNB1 (G protein subunit beta 1) 
30 GOT2 (glutamic-oxaloacetic transaminase 2) 
31 GSTM2 (glutathione S-transferase mu 2) 
32 HADH (hydroxyacyl-CoA dehydrogenase) 
33 HIBADH (3-hydroxyisobutyrate dehydrogenase) 
34 HNRNPA3 (heterogeneous nuclear ribonucleoprotein A3) 
35 HNRNPH2 (heterogeneous nuclear ribonucleoprotein H2) 
36 HPX (hemopexin) 
37 HSPG2 (heparan sulfate proteoglycan 2) 
38 IVD (isovaleryl-CoA dehydrogenase) 
39 KRT10 (keratin 10) 
40 KRT13 (keratin 13) 
41 KRT2 (keratin 2) 
42 KRT5 (keratin 5) 
43 KRT75 (keratin 75) 
44 KRT77 (keratin 77) 
45 LUC7L (LUC7 like) 
46 MACROD1 (MACRO domain containing 1) 
47 MRPL2 (mitochondrial ribosomal protein L2) 
48 MRPL40 (mitochondrial ribosomal protein L40) 
49 MSN (moesin) 
50 MT-CO1 (cytochrome c oxidase subunit I) 
51 MYH9 (myosin heavy chain 9) 
52 NDUFA3 (NADH:ubiquinone oxidoreductase subunit A3) 
53 OAT (ornithine aminotransferase) 
54 PDIA3 (protein disulfide isomerase family A member 3) 
55 PEBP1 (phosphatidylethanolamine binding protein 1) 
56 PGAM1 (phosphoglycerate mutase 1) 




58 PGM1 (phosphoglucomutase 1) 
59 PGM2 (phosphoglucomutase 2) 
60 PPA1 (pyrophosphatase (inorganic) 1) 
61 PPIA (peptidylprolyl isomerase A) 
62 PRDX3 (peroxiredoxin 3) 
63 PRSS1 (protease, serine 1) 
64 RBM39 (RNA binding motif protein 39) 
65 RPL23A (ribosomal protein L23a) 
66 RPL26 (ribosomal protein L26) 
67 RPS27A (ribosomal protein S27a) 
68 SFRP1 (secreted frizzled related protein 1) 
69 SOD2 (superoxide dismutase 2) 
70 TF (transferrin) 
71 TFAM (transcription factor A, mitochondrial) 
72 TNNC1 (troponin C1, slow skeletal and cardiac type) 
73 U2AF1 (U2 small nuclear RNA auxiliary factor 1) 
74 U2AF2 (U2 small nuclear RNA auxiliary factor 2) 
75 UBA1 (ubiquitin like modifier activating enzyme 1) 
 
A.2.8: Statistical Analysis 
All data were analyzed with GraphPad Prism 5. Data are represented as a box and 
whiskers, with median values represented by the horizontal line, 25% to 75% percentiles 
by the box, and the range of values by the whiskers. Where appropriate, a two-way 
ANOVA, one-way ANOVA, or unpaired t-test was performed. Values in the text are 
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